Author: "M Trojano" - Searchworks@Jio Institute Digital Library Search Results

Your search keyword '"M Trojano"' showing total 488 results

Start Over Author "M Trojano"

488 results on '"M Trojano"'

1. Impact of methodological choices in comparative effectiveness studies: application in natalizumab versus fingolimod comparison among patients with multiple sclerosis

Author: M. Lefort, S. Sharmin, J. B. Andersen, S. Vukusic, R. Casey, M. Debouverie, G. Edan, J. Ciron, A. Ruet, J. De Sèze, E. Maillart, H. Zephir, P. Labauge, G. Defer, C. Lebrun-Frenay, T. Moreau, E. Berger, P. Clavelou, J. Pelletier, B. Stankoff, O. Gout, E. Thouvenot, O. Heinzlef, A. Al-Khedr, B. Bourre, O. Casez, P. Cabre, A. Montcuquet, A. Wahab, J. P. Camdessanché, A. Maurousset, H. Ben Nasr, K. Hankiewicz, C. Pottier, N. Maubeuge, D. Dimitri-Boulos, C. Nifle, D. A. Laplaud, D. Horakova, E. K. Havrdova, R. Alroughani, G. Izquierdo, S. Eichau, S. Ozakbas, F. Patti, M. Onofrj, A. Lugaresi, M. Terzi, P. Grammond, F. Grand’Maison, B. Yamout, A. Prat, M. Girard, P. Duquette, C. Boz, M. Trojano, P. McCombe, M. Slee, J. Lechner-Scott, R. Turkoglu, P. Sola, D. Ferraro, F. Granella, V. Shaygannejad, J. Prevost, D. Maimone, O. Skibina, K. Buzzard, A. Van der Walt, R. Karabudak, B. Van Wijmeersch, T. Csepany, D. Spitaleri, S. Vucic, N. Koch-Henriksen, F. Sellebjerg, P. S. Soerensen, C. C. Hilt Christensen, P. V. Rasmussen, M. B. Jensen, J. L. Frederiksen, S. Bramow, H. K. Mathiesen, K. I. Schreiber, H. Butzkueven, M. Magyari, T. Kalincik, and E. Leray
Subjects: Effectiveness, Multiple sclerosis, Propensity score, Indication bias, Causal contrasts, Censoring, Medicine (General), R5-920
Abstract: Abstract Background Natalizumab and fingolimod are used as high-efficacy treatments in relapsing–remitting multiple sclerosis. Several observational studies comparing these two drugs have shown variable results, using different methods to control treatment indication bias and manage censoring. The objective of this empirical study was to elucidate the impact of methods of causal inference on the results of comparative effectiveness studies. Methods Data from three observational multiple sclerosis registries (MSBase, the Danish MS Registry and French OFSEP registry) were combined. Four clinical outcomes were studied. Propensity scores were used to match or weigh the compared groups, allowing for estimating average treatment effect for treated or average treatment effect for the entire population. Analyses were conducted both in intention-to-treat and per-protocol frameworks. The impact of the positivity assumption was also assessed. Results Overall, 5,148 relapsing–remitting multiple sclerosis patients were included. In this well-powered sample, the 95% confidence intervals of the estimates overlapped widely. Propensity scores weighting and propensity scores matching procedures led to consistent results. Some differences were observed between average treatment effect for the entire population and average treatment effect for treated estimates. Intention-to-treat analyses were more conservative than per-protocol analyses. The most pronounced irregularities in outcomes and propensity scores were introduced by violation of the positivity assumption. Conclusions This applied study elucidates the influence of methodological decisions on the results of comparative effectiveness studies of treatments for multiple sclerosis. According to our results, there are no material differences between conclusions obtained with propensity scores matching or propensity scores weighting given that a study is sufficiently powered, models are correctly specified and positivity assumption is fulfilled.
Published: 2022
Full Text: View/download PDF

2. Perampanel during pregnancy: Description of four cases

Author: A.M. Alicino, G. Falcicchio, G. Boero, G. Santarcangelo, T. Francavilla, M. Trojano, and A. La Neve
Subjects: Epilepsy, Perampanel, Pregnancy, Anti-seizure medications (ASMs), Neonatal major malformations, Neurology. Diseases of the nervous system, RC346-429, Neurophysiology and neuropsychology, QP351-495
Abstract: Perampanel (PER) is approved in Italy as an adjunctive treatment for focal-onset seizures (FOS) and generalized tonic-clonic seizures (GTCs), and it could be an alternative to valproate in young women diagnosed with idiopathic generalized epilepsy. Nevertheless, clinical data about the outcome of pregnancies in women exposed to PER are lacking. Here, we report retrospectively collected data from four women suffering from FOS who were exposed to PER during pregnancy. Three pregnancies were carried out with PER as add-on therapy during the entire gestation (8 mg/day in two patients and 6 mg/day in one), without seizure frequency variations. The fourth patient started PER 2 mg/day as monotherapy during the 13th week of pregnancy due to seizure relapse and continued it until delivery with complete seizure control. All pregnancies showed good outcomes, and their newborns did not possess major congenital malformations. Apgar scores and auxological parameters at birth were normal. Fetal pathology in follow-up during pregnancies was absent in all cases. In our patients PER was well tolerated and appeared safe for the fetuses and did not result in major malformations or adverse events at birth. Nevertheless, this is a report involving a small number of patients and it does not suggest the general use of PER is safe during pregnancy.
Published: 2021
Full Text: View/download PDF

3. POSC400 Epidemiology and Patients' Characteristics in Multiple Sclerosis: An Analysis from the Italian Multiple Sclerosis Registry

Author: M Nica, P Iaffaldano, and M Trojano
Subjects: Health Policy, Public Health, Environmental and Occupational Health
Published: 2022

4. Neuraxial analgesia is not associated with an increased risk of post-partum relapses in MS

Author: Caroline Lavie, Fabien Rollot, Françoise Durand-Dubief, Romain Marignier, Iuliana Ionescu, Romain Casey, Thibault Moreau, Patricia Tourniaire, Michael Hutchinson, Marie Béatrice D’Hooghe, David-Axel Laplaud, Pierre Clavelou, Jérôme De Sèze, Marc Debouverie, David Brassat, Jean Pelletier, Christine Lebrun-Frenay, Emmanuelle Le Page, Giovanni Castelnovo, Eric Berger, Patrick Hautecoeur, Olivier Heinzlef, Luca Durelli, Marinella Clerico, Maria Trojano, Francesco Patti, Sandra Vukusic, A. Alpérovitch, H. Carton, M.B. d’Hooghe, O. Hommes, M. Hutchinson, P. Adeleine, A. Biron, P. Cortinovis-Tourniaire, J. Grimaud, M. Hours, T. Moreau, S. Vukusic, C. Confavreux, G. Chauplannaz, D. Latombe, M. Clanet, G. Lau, L. Rumbach, J.Y. Goas, F. Rouhart, A. Mazingue, E. Roullet, M. Madigand, P. Hautecoeur, P. Brunet, G. Edan, C. Allaire, G. Riffault, J. Leche, T. Benoit, C. Simonin, F. Ziegler, J.C. Baron, Y. Rivrain, R. Dumas, D. Loche, J.C. Bourrin, B. Huttin, B. Delisse, I. Gibert, C. Boulay, M. Verceletto, G. Durand, G. Bonneviot, R. Gil, M.A. Hedreville, C. Belair, R.J. Poitevin, J.L. Devoize, P. Wyremblewski, F. Delestre, A. Setiey, G. Comi, M. Filippi, A. Ghezzi, V. Martinelli, P. Rossi, M. Zaffaroni, M.R. Tola, M.P. Amato, C. Fioretti, G. Meucci, M. Inglese, G.L. Mancardi, D. Gambi, A. Thomas, M. Cavazzuti, A. Citterio, A. Heltberg, H.J. Hansen, O. Fernandez, F. Romero, T. Arbizu, J.J. Hernandez, C. De Andres de Frutos, D. Geffner Sclarky, Y. Aladro Benito, P. Reyes Yanes, M Aguilar, J.A. Burguera, R. Yaya, W. Bonakim Dib, D. Arzua-Mouronte, C.J.M. Sindic, R. Medaer, H. Roose, K.M.J. Geens, D. Guillaume, M. Van Zandycke, J. Janssens, M. Cornette, L. Mol, F. Weilbach, P. Flachenecker, H.P. Hartung, J. Haas, I. Tendolkar, E. Sindrn, H.W. Kölmel, D. Reichel, M. Rauch, S. Preuss, S. Poser, E. Mauch, S. Strausser-Fuchs, H. Kolleger, S. Hawkins, S.J.L. Howell, J.E. Rees, A. Thompson, M. Johnson, M. Boggild, R.P. Gregory, D. Bates, I. Bone, C. Polman, S. Frequin, P. Jongen, J. Correia de Sa, M.E. Rio, S. Huber, J. Lechner-Scott, L. Kappos, I. Ionescu, C. Cornu, M. El-Etr, E.E. Baulieu, M Schumacher, D.H. Miller, M. Pugeat, C. d’Archangues, J. Conard, J. Ménard, R. Sitruk-Ware, C. Pelissier, S. Dat, J. Belaïsch-Allard, N. Athéa, D. Büschsenschutz, O. Lyon-Caen, R. Gonsette, J.P. Boissel, P. Ffrench, F. Durand-Dubief, F. Cotton, C. Pachai, L. Bracoud, G. Androdias, R. Marignier, D.A. Laplaud, S. Wiertlewski, C. Lanctin-Garcia, G. Couvreur, G. Madinier, P. Clavelou, F. Taithe, D. Aufauvre, N. Guy, A. Ferrier, J. De Sèze, N. Collongues, M. Debouverie, F. Viala, D. Brassat, A. Gerdelat-Mas, P. Henry, J. Pelletier, A. Rico-Lamy, C. Lebrun-Frenay, E. Lepage, V. Deburghraeve, G. Castelnovo, E. Berger, M. Blondiau, O. Heinzlef, M. Coustans, C. Clerc, L. Rieu, M. Lauxerois, G. Hinzelin, J.C. Ouallet, D. Minier, P. Vion, N. Gromaire-Fayolle, N. Derache, E. Thouvenot, M. Sallansonnet-Froment, P. Tourniaire, L. Toureille, F. Borgel, B. Stankoff, C. Moroianu, A.M. Guennoc, C.L. Tournier-Gervason, S. Peysson, M. Trojano, F. Patti, E. D’Amico, L. Motti, L. Durelli, A. Tavella, Hôpital neurologique et neurochirurgical Pierre Wertheimer [CHU - HCL], Hospices Civils de Lyon (HCL), Observatoire Français de la Sclérose En Plaques [Lyon] (OFSEP), Service de neurologie fonctionnelle et d'épileptologie [Hôpital Pierre Wertheimer-HCL], Hospices Civils de Lyon (HCL)-Hospices Civils de Lyon (HCL), Centre de recherche en neurosciences de Lyon - Lyon Neuroscience Research Center (CRNL), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Université Jean Monnet [Saint-Étienne] (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Service de Neurologie générale, vasculaire et dégénérative (CHU de Dijon), Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Centre Hospitalier Henri Duffaut (Avignon), National MS Center Melsbroek, Vrije Universiteit Brussel [Bruxelles] (VUB), Vrije Universiteit Brussel (VUB), Centre de Recherche en Transplantation et Immunologie (U1064 Inserm - CRTI), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN), Service de Neurologie [CHU Clermont-Ferrand], CHU Gabriel Montpied [Clermont-Ferrand], CHU Clermont-Ferrand-CHU Clermont-Ferrand-CHU Estaing [Clermont-Ferrand], CHU Clermont-Ferrand, Neuro-Dol (Neuro-Dol), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Clermont Auvergne (UCA), Laboratoire de Neuroimagerie in Vivo (LNV), CHU Strasbourg-Centre National de la Recherche Scientifique (CNRS), Les Hôpitaux Universitaires de Strasbourg (HUS), Service de neurologie [CHRU Nancy], Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Maladies chroniques, santé perçue, et processus d'adaptation (APEMAC), Université de Lorraine (UL), Neurologie vasculaire, pathologie neuro-dégénérative et explorations fonctionnelles du système nerveux [Toulouse], Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-CHU Toulouse [Toulouse], Centre de Physiopathologie Toulouse Purpan (CPTP), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Centre de résonance magnétique biologique et médicale (CRMBM), Aix Marseille Université (AMU)-Assistance Publique - Hôpitaux de Marseille (APHM)-Centre National de la Recherche Scientifique (CNRS), Hôpital de la Timone [CHU - APHM] (TIMONE), Centre Hospitalier Universitaire de Nice (CHU Nice), Université Côte d'Azur (UCA), Centre d'Investigation Clinique [Rennes] (CIC), Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Hôpital Pontchaillou-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre Hospitalier Universitaire de Nîmes (CHU Nîmes), Service de Neurologie [CHRU Besançon], Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Groupe Hospitalier de l'Institut Catholique de Lille (GHICL), Université catholique de Lille (UCL), centre hospitalier intercommunal de Poissy/Saint-Germain-en-Laye - CHIPS [Poissy], Università degli studi di Torino = University of Turin (UNITO), University of Catania [Italy], Hospices Civils de Lyon, Departement de Neurologie (HCL), Biostatistiques santé, Département biostatistiques et modélisation pour la santé et l'environnement [LBBE], Laboratoire de Biométrie et Biologie Evolutive - UMR 5558 (LBBE), Université de Lyon-Université de Lyon-Institut National de Recherche en Informatique et en Automatique (Inria)-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de Recherche en Informatique et en Automatique (Inria)-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS)-Laboratoire de Biométrie et Biologie Evolutive - UMR 5558 (LBBE), Université de Lyon-Université de Lyon-Institut National de Recherche en Informatique et en Automatique (Inria)-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS), CHU Toulouse [Toulouse], Protéines membranaires transductrices d'énergie (PMTE), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Centre National de la Recherche Scientifique (CNRS), Institut des Géosciences de l’Environnement (IGE), Institut de Recherche pour le Développement (IRD)-Institut polytechnique de Grenoble - Grenoble Institute of Technology (Grenoble INP )-Institut national des sciences de l'Univers (INSU - CNRS)-Centre National de la Recherche Scientifique (CNRS)-Université Grenoble Alpes [2016-2019] (UGA [2016-2019]), Centre de Recherches sur les Macromolécules Végétales (CERMAV ), Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS)-Université Grenoble Alpes [2016-2019] (UGA [2016-2019]), Environnement Ville Société (EVS), École normale supérieure - Lyon (ENS Lyon)-École des Mines de Saint-Étienne (Mines Saint-Étienne MSE), Institut Mines-Télécom [Paris] (IMT)-Institut Mines-Télécom [Paris] (IMT)-Université Lumière - Lyon 2 (UL2)-Université Jean Moulin - Lyon 3 (UJML), Université de Lyon-Université de Lyon-Institut National des Sciences Appliquées de Lyon (INSA Lyon), Université de Lyon-Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Université Jean Monnet [Saint-Étienne] (UJM)-École Nationale des Travaux Publics de l'État (ENTPE)-École nationale supérieure d'architecture de Lyon (ENSAL)-Centre National de la Recherche Scientifique (CNRS), Solvay (France), Laboratoire des Mécanismes et Transfert en Géologie (LMTG), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Observatoire Midi-Pyrénées (OMP), Institut de Recherche pour le Développement (IRD)-Institut national des sciences de l'Univers (INSU - CNRS)-Centre National d'Études Spatiales [Toulouse] (CNES)-Centre National de la Recherche Scientifique (CNRS)-Université Fédérale Toulouse Midi-Pyrénées-Météo-France -Institut de Recherche pour le Développement (IRD)-Institut national des sciences de l'Univers (INSU - CNRS)-Centre National d'Études Spatiales [Toulouse] (CNES)-Centre National de la Recherche Scientifique (CNRS)-Météo-France -Centre National de la Recherche Scientifique (CNRS), Institute of Evolutionary Biology, University of Edinburgh, Université de Lille, Sciences et Technologies, Service de Génétique Médicale [CHU Necker], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Necker - Enfants Malades [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Différenciation, interaction, activation et migration des sous-populations lymphocitaires humaines, Institut National de la Santé et de la Recherche Médicale (INSERM), Centre de Recherche en Acquisition et Traitement de l'Image pour la Santé (CREATIS), Université de Lyon-Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Hospices Civils de Lyon (HCL)-Université Jean Monnet [Saint-Étienne] (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Motricité, interactions, performance EA 4334 / Movement - Interactions - Performance (MIP), Le Mans Université (UM)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Université de Nantes - UFR des Sciences et Techniques des Activités Physiques et Sportives (UFR STAPS), Laboratoire Ecologie Fonctionnelle et Environnement (ECOLAB), Institut Ecologie et Environnement (INEE), Centre National de la Recherche Scientifique (CNRS)-Centre National de la Recherche Scientifique (CNRS)-Université Toulouse III - Paul Sabatier (UT3), Institut de Recherche pour le Développement (IRD)-Institut national des sciences de l'Univers (INSU - CNRS)-Centre National d'Études Spatiales [Toulouse] (CNES)-Centre National de la Recherche Scientifique (CNRS)-Université Fédérale Toulouse Midi-Pyrénées-Météo-France -Institut de Recherche pour le Développement (IRD)-Institut national des sciences de l'Univers (INSU - CNRS)-Centre National d'Études Spatiales [Toulouse] (CNES)-Centre National de la Recherche Scientifique (CNRS)-Météo-France -Centre National de la Recherche Scientifique (CNRS)-Institut National Polytechnique (Toulouse) (Toulouse INP), Université Fédérale Toulouse Midi-Pyrénées, Laboratoire de Chimie Physique D'Orsay (LCPO), Université Paris-Sud - Paris 11 (UP11)-Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS), RMN et optique : De la mesure au biomarqueur, Université de Lyon-Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Hospices Civils de Lyon (HCL)-Université Jean Monnet [Saint-Étienne] (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Claude Bernard Lyon 1 (UCBL), Department of Neurology, CHU Lyon, Institut de Recherche de Chimie Paris (IRCP), Ecole Nationale Supérieure de Chimie de Paris - Chimie ParisTech-PSL (ENSCP), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS)-Ministère de la Culture (MC), Hôpital de Hautepierre [Strasbourg], Laboratoire de Réactivité des Surfaces et des Interfaces (LRSI), Département de Physico-Chimie (DPC), CEA-Direction des Energies (ex-Direction de l'Energie Nucléaire) (CEA-DES (ex-DEN)), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Paris-Saclay-CEA-Direction des Energies (ex-Direction de l'Energie Nucléaire) (CEA-DES (ex-DEN)), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Paris-Saclay, Empenn, Institut National de la Santé et de la Recherche Médicale (INSERM)-Inria Rennes – Bretagne Atlantique, Institut National de Recherche en Informatique et en Automatique (Inria)-Institut National de Recherche en Informatique et en Automatique (Inria)-SIGNAUX ET IMAGES NUMÉRIQUES, ROBOTIQUE (IRISA-D5), Institut de Recherche en Informatique et Systèmes Aléatoires (IRISA), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Institut National des Sciences Appliquées - Rennes (INSA Rennes), Institut National des Sciences Appliquées (INSA)-Université de Rennes (UNIV-RENNES)-Institut National des Sciences Appliquées (INSA)-Université de Bretagne Sud (UBS)-École normale supérieure - Rennes (ENS Rennes)-Institut National de Recherche en Informatique et en Automatique (Inria)-CentraleSupélec-Centre National de la Recherche Scientifique (CNRS)-IMT Atlantique Bretagne-Pays de la Loire (IMT Atlantique), Institut Mines-Télécom [Paris] (IMT)-Institut Mines-Télécom [Paris] (IMT)-Université de Rennes 1 (UR1), Institut Mines-Télécom [Paris] (IMT)-Institut Mines-Télécom [Paris] (IMT)-Institut de Recherche en Informatique et Systèmes Aléatoires (IRISA), Institut National des Sciences Appliquées (INSA)-Université de Rennes (UNIV-RENNES)-Institut National des Sciences Appliquées (INSA)-Université de Bretagne Sud (UBS)-École normale supérieure - Rennes (ENS Rennes)-CentraleSupélec-Centre National de la Recherche Scientifique (CNRS)-IMT Atlantique Bretagne-Pays de la Loire (IMT Atlantique), Institut Mines-Télécom [Paris] (IMT)-Institut Mines-Télécom [Paris] (IMT), Service de Neurologie [Rennes] = Neurology [Rennes], CHU Pontchaillou [Rennes], Biologie des Interactions Neurones / Glie, Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM), Fondation pour l'Aide à la Recherche sur la Sclérose en Plaques, European Leukodystrophies Association, PHRC National, Lipides - Nutrition - Cancer (U866) (LNC), Université de Bourgogne (UB)-Institut National de la Santé et de la Recherche Médicale (INSERM)-AgroSup Dijon - Institut National Supérieur des Sciences Agronomiques, de l'Alimentation et de l'Environnement-Ecole Nationale Supérieure de Biologie Appliquée à la Nutrition et à l'Alimentation de Dijon (ENSBANA), Université Jean Monnet [Saint-Étienne] (UJM)-Hospices Civils de Lyon (HCL)-Institut National des Sciences Appliquées de Lyon (INSA Lyon), Université de Lyon-Institut National des Sciences Appliquées (INSA)-Université de Lyon-Institut National des Sciences Appliquées (INSA)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Jean Monnet [Saint-Étienne] (UJM)-Hospices Civils de Lyon (HCL)-Institut National des Sciences Appliquées de Lyon (INSA Lyon), Université de Lyon-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM), Pierre Wertheimer, Département de Neurologie, Laboratoire de Mathématiques (LAMA), Centre National de la Recherche Scientifique (CNRS)-Université Savoie Mont Blanc (USMB [Université de Savoie] [Université de Chambéry]), Cardiovasculaire, métabolisme, diabétologie et nutrition (CarMeN), Hospices Civils de Lyon (HCL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National des Sciences Appliquées de Lyon (INSA Lyon), Université de Lyon-Institut National de la Recherche Agronomique (INRA), Nottingham Scientific Limited, Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-CHU Toulouse [Toulouse]-Hôpital Purpan [Toulouse], Assistance Publique - Hôpitaux de Marseille (APHM)-Aix Marseille Université (AMU)-Centre National de la Recherche Scientifique (CNRS), Service de neurologie [Rennes], Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES), Université de Turin, Università degli studi di Torino (UNITO), University of Bari Aldo Moro (UNIBA), Department of Neurosciences, Università degli studi di Catania [Catania], Centre de recherche en neurosciences de Lyon (CRNL), Neuroépidémiologie, Institut de Physique du Globe de Paris (IPGP), Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut national des sciences de l'Univers (INSU - CNRS)-IPG PARIS-Université Paris Diderot - Paris 7 (UPD7)-Université de La Réunion (UR)-Centre National de la Recherche Scientifique (CNRS), Institut national des sciences de l'Univers (INSU - CNRS)-Centre National de la Recherche Scientifique (CNRS)-Institut polytechnique de Grenoble - Grenoble Institute of Technology (Grenoble INP )-Institut de Recherche pour le Développement (IRD)-Université Grenoble Alpes [2016-2019] (UGA [2016-2019]), Institut National des Sciences Appliquées de Lyon (INSA Lyon), Université de Lyon-Institut National des Sciences Appliquées (INSA)-Université de Lyon-Institut National des Sciences Appliquées (INSA)-Centre National de la Recherche Scientifique (CNRS)-École nationale supérieure d'architecture de Lyon (ENSAL)-École des Mines de Saint-Étienne (Mines Saint-Étienne MSE), Institut Mines-Télécom [Paris] (IMT)-Institut Mines-Télécom [Paris] (IMT)-École Nationale des Travaux Publics de l'État (ENTPE)-Université Jean Monnet [Saint-Étienne] (UJM)-Université Jean Moulin - Lyon 3 (UJML), Université de Lyon-Université Lumière - Lyon 2 (UL2)-École normale supérieure - Lyon (ENS Lyon), Météo France-Centre National d'Études Spatiales [Toulouse] (CNES)-Université Fédérale Toulouse Midi-Pyrénées-Centre National de la Recherche Scientifique (CNRS)-Institut de Recherche pour le Développement (IRD)-Météo France-Centre National d'Études Spatiales [Toulouse] (CNES)-Centre National de la Recherche Scientifique (CNRS)-Institut de Recherche pour le Développement (IRD)-Centre National de la Recherche Scientifique (CNRS), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut Ecologie et Environnement (INEE), Centre National de la Recherche Scientifique (CNRS)-Centre National de la Recherche Scientifique (CNRS)-Institut National Polytechnique (Toulouse) (Toulouse INP), Université Fédérale Toulouse Midi-Pyrénées-Observatoire Midi-Pyrénées (OMP), Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS)-Ecole Nationale Supérieure de Chimie de Paris - Chimie ParisTech-PSL (ENSCP), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Ministère de la Culture (MC), Université de Bretagne Sud (UBS)-Institut National des Sciences Appliquées - Rennes (INSA Rennes), Institut National des Sciences Appliquées (INSA)-Université de Rennes (UNIV-RENNES)-Institut National des Sciences Appliquées (INSA)-Université de Rennes (UNIV-RENNES)-Institut National de Recherche en Informatique et en Automatique (Inria)-École normale supérieure - Rennes (ENS Rennes)-Centre National de la Recherche Scientifique (CNRS)-Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-CentraleSupélec-IMT Atlantique Bretagne-Pays de la Loire (IMT Atlantique), Institut Mines-Télécom [Paris] (IMT)-Institut Mines-Télécom [Paris] (IMT)-Université de Bretagne Sud (UBS)-Institut National des Sciences Appliquées - Rennes (INSA Rennes), Institut National des Sciences Appliquées (INSA)-Université de Rennes (UNIV-RENNES)-Institut National des Sciences Appliquées (INSA)-Université de Rennes (UNIV-RENNES)-École normale supérieure - Rennes (ENS Rennes)-Centre National de la Recherche Scientifique (CNRS)-Université de Rennes 1 (UR1), Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National de la Santé et de la Recherche Médicale (INSERM), Lavie, Caroline, Rollot, Fabien, Durand-Dubief, Françoise, Marignier, Romain, Ionescu, Iuliana, Casey, Romain, Moreau, Thibault, Tourniaire, Patricia, Hutchinson, Michael, D’Hooghe, Marie Béatrice, Laplaud, David-Axel, Clavelou, Pierre, De Sèze, Jérôme, Debouverie, Marc, Brassat, David, Pelletier, Jean, Lebrun-Frenay, Christine, Le Page, Emmanuelle, Castelnovo, Giovanni, Berger, Eric, Hautecoeur, Patrick, Heinzlef, Olivier, Durelli, Luca, Clerico, Marinella, Trojano, Maria, Patti, Francesco, Vukusic, Sandra, on behalf of PRIMS and POPARTMUS, Investigator, Filippi, Massimo, Université de Lyon-Université de Lyon-Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Université de Toulouse (UT)-Université de Toulouse (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Université de Rennes (UR)-Hôpital Pontchaillou-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre hospitalier intercommunal de Poissy/Saint-Germain-en-Laye - CHIPS [Poissy], Environnement, Ville, Société (EVS), École normale supérieure de Lyon (ENS de Lyon)-École des Mines de Saint-Étienne (Mines Saint-Étienne MSE), Université de Lyon-Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Université Jean Monnet - Saint-Étienne (UJM)-École Nationale des Travaux Publics de l'État (ENTPE)-École nationale supérieure d'architecture de Lyon (ENSAL)-Centre National de la Recherche Scientifique (CNRS), Université de Lyon-Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Université de Lyon-Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Claude Bernard Lyon 1 (UCBL), Neuroimagerie: méthodes et applications (Empenn), Université de Rennes (UR)-Institut National des Sciences Appliquées - Rennes (INSA Rennes), Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Université de Bretagne Sud (UBS)-École normale supérieure - Rennes (ENS Rennes)-Institut National de Recherche en Informatique et en Automatique (Inria)-CentraleSupélec-Centre National de la Recherche Scientifique (CNRS)-IMT Atlantique (IMT Atlantique), Institut Mines-Télécom [Paris] (IMT)-Institut Mines-Télécom [Paris] (IMT)-Université de Rennes (UR)-Institut National des Sciences Appliquées - Rennes (INSA Rennes), Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Université de Bretagne Sud (UBS)-École normale supérieure - Rennes (ENS Rennes)-CentraleSupélec-Centre National de la Recherche Scientifique (CNRS)-IMT Atlantique (IMT Atlantique), Institut National de la Recherche Agronomique (INRA)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Hospices Civils de Lyon (HCL), Laboratoire de glaciologie et géophysique de l'environnement (LGGE), Observatoire des Sciences de l'Univers de Grenoble (OSUG), Université Savoie Mont Blanc (USMB [Université de Savoie] [Université de Chambéry])-Institut polytechnique de Grenoble - Grenoble Institute of Technology (Grenoble INP)-Institut national de recherche en sciences et technologies pour l'environnement et l'agriculture (IRSTEA)-Université Joseph Fourier - Grenoble 1 (UJF)-Institut national des sciences de l'Univers (INSU - CNRS)-Centre National de la Recherche Scientifique (CNRS)-Université Grenoble Alpes (UGA)-Université Savoie Mont Blanc (USMB [Université de Savoie] [Université de Chambéry])-Institut polytechnique de Grenoble - Grenoble Institute of Technology (Grenoble INP)-Institut national de recherche en sciences et technologies pour l'environnement et l'agriculture (IRSTEA)-Université Joseph Fourier - Grenoble 1 (UJF)-Institut national des sciences de l'Univers (INSU - CNRS)-Centre National de la Recherche Scientifique (CNRS)-Université Grenoble Alpes (UGA)-Centre National de la Recherche Scientifique (CNRS), Centre de Recherches sur les Macromolécules Végétales (CERMAV), Université Joseph Fourier - Grenoble 1 (UJF)-Centre National de la Recherche Scientifique (CNRS)-Université Grenoble Alpes (UGA), Université Fédérale Toulouse Midi-Pyrénées-Centre National de la Recherche Scientifique (CNRS), Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-CHU Necker - Enfants Malades [AP-HP], Laboratoire Motricité, Interactions, Performance, Université de Nantes (UN), Université Fédérale Toulouse Midi-Pyrénées-Centre National de la Recherche Scientifique (CNRS)-Institut National Polytechnique (Toulouse) (Toulouse INP), Université Paris-Sud - Paris 11 (UP11)-Centre National de la Recherche Scientifique (CNRS), Université Savoie Mont Blanc (USMB [Université de Savoie] [Université de Chambéry])-Centre National de la Recherche Scientifique (CNRS), Ecole Nationale Supérieure de Chimie de Paris- Chimie ParisTech-PSL (ENSCP)-Centre National de la Recherche Scientifique (CNRS)-Ministère de la Culture (MC), Centre Hospitalier Universitaire de Strasbourg (CHU de Strasbourg ), CEA-Direction de l'Energie Nucléaire (CEA-DEN), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Paris-Saclay-CEA-Direction de l'Energie Nucléaire (CEA-DEN), Centre Hospitalier Régional Universitaire de Nîmes (CHRU Nîmes), Service de neurologie [Besançon], Centre Hospitalier Régional Universitaire [Besançon] (CHRU Besançon)-Hôpital Jean Minjoz, Service de Neurologie [CHU Besançon], Centre Hospitalier Régional Universitaire [Besançon] (CHRU Besançon), Service de Neurologie [Rennes], Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Hôpital Pontchaillou-CHU Pontchaillou [Rennes], Clinical sciences, Neuroprotection & Neuromodulation, and Neurology
Subjects: relapses, Neurology, [SDV]Life Sciences [q-bio], MESH: Pregnancy Complications / physiopathology, 0302 clinical medicine, MESH: Pregnancy, Anesthesia, Conduction, Recurrence, MESH: Anesthesia, Conduction / adverse effects, 030212 general & internal medicine, ComputingMilieux_MISCELLANEOUS, reproductive and urinary physiology, relapse, Postpartum Period, post-partum, MESH: Follow-Up Studies, MESH: Multiple Sclerosis / physiopathology, Obstetrical Analgesia, MESH: Multiple Sclerosis / chemically induced, Anesthesia, Female, pregnancy, Adult, medicine.medical_specialty, Clinical Neurology, Multiple sclerosis, MESH: Postpartum Period, 03 medical and health sciences, medicine, Humans, Multiple sclerosi, Post partum, Retrospective Studies, Pregnancy, MESH: Humans, MESH: Pregnancy Complications / chemically induced, business.industry, Neurotoxicity, MESH: Adult, MESH: Retrospective Studies, neuraxial analgesia, medicine.disease, MESH: Recurrence, Multiple sclerosis, neuraxial analgesia, post-partum, pregnancy, Pregnancy Complications, Increased risk, Neurology (clinical), [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, business, MESH: Female, 030217 neurology & neurosurgery, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology, Follow-Up Studies
Abstract: Background: Obstetrical analgesia remains a matter of controversy because of the fear of neurotoxicity of local anesthetics on demyelinated fibers or their potential relationship with subsequent relapses. Objective: To assess the impact of neuraxial analgesia on the risk of relapse during the first 3 months post-partum, with a focus on women who experienced relapses during pregnancy. Methods: We analyzed data of women followed-up prospectively during their pregnancies and at least 3 months post-partum, collected in the Pregnancy in Multiple Sclerosis (PRIMS) and Prevention of Post-Partum Relapses with Progestin and Estradiol in Multiple Sclerosis (POPARTMUS) studies between 1992–1995 and 2005–2012, respectively. The association of neuraxial analgesia with the occurrence of a post-partum relapse was estimated by logistic regression analysis. Results: A total of 389 women were included, 215 from PRIMS and 174 from POPARTMUS. In total, 156 women (40%) had neuraxial analgesia. Overall, 24% experienced a relapse during pregnancy and 25% in the 3 months post-partum. Women with a pregnancy relapse were more likely to have a post-partum relapse (odds ratio (OR) = 1.83, p = 0.02), independently of the use of neuraxial analgesia. There was no association between neuraxial analgesia and post-partum relapse (OR = 1.08, p = 0.78). Conclusion: Neuraxial analgesia was not associated with an increased risk of post-partum relapses, whatever multiple sclerosis (MS) activity during pregnancy.
Published: 2019

5. Predictor of disability accrual in ultiple sclerosis patients on first-line therapy

Author: T. Spelman, V. Jokubaitis, G. Izquierdo, P. Duquette, F. Grand’Maison, P. Grammond, R. Hupperts, E. Havrdova, C. Oreja Guevara, R. Alroughani, T. Petersen, J. Lechner Scott, C. Boz, H. Butzkueven, LUGARESI, ALESSANDRA, M. Trojano, for the MSBase Study Group, T. Spelman, V. Jokubaiti, G. Izquierdo, P. Duquette, F. Grand’Maison, P.Grammond, R. Huppert, E. Havrdova, C. Oreja-Guevara, R. Alroughani, T. Petersen, J. Lechner-Scott, C. Boz, H. Butzkueven, A. Lugaresi, M. Trojano, and for the MSBase Study Group.
Subjects: multiple sclerosis, prognosis, treatment, interferon, glatiramer acetate
Published: 2014

6. Predisctors of definite multiple sclerosis in patients with a pediatric onset first demyelinating clinical attack

Author: P. Iaffaldano, G. Lucisano, A. Ghezzi, G. Comi, V. Brescia Morra, F. Patti, LUGARESI, ALESSANDRA, C. Pozzilli, M. Amato, G. Salemi, E. Millefiorini, G. Lus, G. Zimatore, D. Maimone, G. Coniglio, R. Bergamaschi, M. Marrosu, G. Tedeschi, B. Ardito, G. Giuliani, C. Avolio, E. Montanari, M. Simone, L. Margari, V. Lepore, M. Trojano, P. Iaffaldano, G. Lucisano, A. Ghezzi, G. Comi, V. Brescia Morra, F. Patti, A. Lugaresi, C. Pozzilli, M. Amato, G. Salemi, E. Millefiorini, G. Lu, G. Zimatore, D. Maimone, G. Coniglio, R. Bergamaschi, M. Marrosu, G. Tedeschi, B. Ardito, G. Giuliani, C. Avolio, E. Montanari, M. Simone, L. Margari, V. Lepore, and M. Trojano
Subjects: multiple sclerosis, clinically isolated syndrome, pediatric, prognosis
Published: 2014

7. The risk of relapse after natalizumab discontinuation could be reduced? Results from the Imedweb Registry

Author: P. Iaffaldano, V. Lepore, G. Lucisano, C. Pozzilli, V. Brescia Morra, A. Ghezzi, E. Millefiorini, F. Patti, LUGARESI, ALESSANDRA, G. Zimatore, M. Marrosu, M. Amato, A. Bertolotto, R. Bergamaschi, F. Granella, G. Coniglio, G. Tedeschi, D. Paolicelli, C. Tortorella, P. Sola, G. Lus, M. Ferrò, G. Iuliano, F. Corea, A. Protti, P. Cavalla, E. Montanari, G. Comi, M. Trojano, P. Iaffaldano, V. Lepore, G. Lucisano, C. Pozzilli, V. Brescia Morra, A. Ghezzi, E. Millefiorini, F. Patti, A. Lugaresi, G. Zimatore, M. Marrosu, M. Amato, A. Bertolotto, R. Bergamaschi, F. Granella, G. Coniglio, G. Tedeschi, D. Paolicelli, C. Tortorella, P. Sola, G. Lu, M. Ferrò, G. Iuliano, F. Corea, A. Protti, P. Cavalla, E. Montanari, G. Comi, and M. Trojano
Subjects: multiple sclerosis, database, natalizumab, treatment
Published: 2014

8. Postpartum relapses increase the risk of disability progression in multiple sclerosis: the role of disease modifying drugs

Author: E. Portaccio, A. Ghezzi, B. Hakiki, A. Sturchio, V. Martinelli, L. Moiola, F. Patti, G. L. Mancardi, C. Solaro, M. R. Tola, C. Pozzilli, L. De Giglio, R. Totaro, G. De Luca, D. Paolicelli, M. G. Marrosu, G. Comi, M. Trojano, M. P. Amato, A. MP, P. E, H. B, S. A, P. L, G. M, R. L, P. E, S. G, G. A, R. A, Z. M, M. V, R. M, M. L, C. G, P. A, S. C, M. R, C. P, M. S, B. R, M. G, C. E, S. C, T. MR, L. Caniatti, F. Granella, P. Immovilli, P. Annunziata, L. De Santi, K. Plewnia, L. Guidi, M. Bartolozzi, M. Mazzoni, A. Carolei, M. Rossi, A. Lugaresi, V. Di Tommaso, A. Carrozzo, M. D'Onghia, M. Marrosu, L. Musu, L. Carmela, S. L. Fermo, LUGARESI, ALESSANDRA, Portaccio, E, Ghezzi, A, Hakiki, B, Sturchio, A, Martinelli, V, Moiola, L, Patti, F, Mancardi, Gl, Solaro, C, Tola, Mr, Pozzilli, C, De Giglio, L, Totaro, R, Lugaresi, A, De Luca, G, Paolicelli, D, Marrosu, Mg, Comi, Giancarlo, Trojano, M, Amato, Mp, MS Study Group of the Italian Neurological, Society, Radaelli, Marta, E. Portaccio, A. Ghezzi, B. Hakiki, A. Sturchio, V. Martinelli, L. Moiola, F. Patti, G. L. Mancardi, C. Solaro, M. R. Tola, C. Pozzilli, L. De Giglio, R. Totaro, A. Lugaresi, G. De Luca, D. Paolicelli, M. G. Marrosu, G. Comi, M. Trojano, M. P. Amato, A. MP, P. E, H. B, S. A, P. L, G. M, R. L, S. G, G. A, R. A, Z. M, M. V, R. M, M. L, C. G, P. A, S. C, M. R, C. P, M. S, B. R, M. G, C. E, T. MR, L. Caniatti, F. Granella, P. Immovilli, P. Annunziata, L. De Santi, K. Plewnia, L. Guidi, M. Bartolozzi, M. Mazzoni, A. Carolei, M. Rossi, V. Di Tommaso, A. Carrozzo, M. D'Onghia, M. Marrosu, L. Musu, L. Carmela, and S. L. Fermo
Subjects: Adult, medicine.medical_specialty, Multiple Sclerosis, Databases, Factual, Anti-Inflammatory Agents, Age of Onset, Disability Evaluation, Female, Follow-Up Studies, Humans, Interferon-beta, Italy, Methylprednisolone, Postpartum Period, Pregnancy, Pregnancy Outcome, Prospective Studies, Recurrence, Risk Assessment, Risk Factors, Surgery, Neurology (clinical), Psychiatry and Mental Health, relapses, postpartum, multiple sclerosis, prognosis, Databases, Arts and Humanities (miscellaneous), Internal medicine, Medicine, Prospective cohort study, Factual, Expanded Disability Status Scale, business.industry, Multiple sclerosis, medicine.disease, Psychiatry and Mental health, Physical therapy, Age of onset, business, Live birth, Risk assessment, Postpartum period
Abstract: OBJECTIVE: To assess relapses, disability progression and the role of disease modifying drugs (DMDs) in the year after delivery in women with multiple sclerosis (MS). METHODS: We prospectively followed-up pregnancies occurring between 2002 and 2008 in women with MS, recruited from 21 Italian MS centres. The risk of relapses and disability progression in the year after delivery was assessed using time-dependent Cox regression analysis. RESULTS: 350 out of 423 pregnancies were assessed (pregnancies not resulting in live birth and with a postpartum follow-up period shorter than 1 year were excluded from the analysis). 148 patients (42.3%) had at least one relapse in the year after delivery. An Expanded Disability Status Scale (EDSS) score at conception ≥2.0 (HR=1.4; 95% CI 1.1 to 2.0; p=0.046) and a higher number of relapses before (HR=1.5; 95% CI 1.2 to 1.8; p
Published: 2014

9. Pregnancy outcomes and disease activity after exposure to natalizumab in patients with multiple sclerosis

Author: E. Portaccio, B. Hakiki, L. Pastò, M. Giannini, C. Pecori, L. Razzolini, C. Tortorella, M. D’Onghia, M. Trojano, E. Cocco, M. Melis, M. Morrosu, V. Di Tommaso, D. Farina, P. Annovazzi, A. Ghezzi, C. Gasperini, A. Iudice, R. Fantozzi, P. Bellantonio, S. Messina, F. Patti, S. Masera, P. Cavalla, A. Protti, M. Rossi, R. Totaro, M. Amato, LUGARESI, ALESSANDRA, E. Portaccio, B. Hakiki, L. Pastò, M. Giannini, C. Pecori, L. Razzolini, C. Tortorella, M. D’Onghia, M. Trojano, E. Cocco, M. Meli, M. Morrosu, V. Di Tommaso, D. Farina, A. Lugaresi, P. Annovazzi, A. Ghezzi, C. Gasperini, A. Iudice, R. Fantozzi, P.Bellantonio, S. Messina, F. Patti, S. Masera, P. Cavalla, A. Protti, M. Rossi, R. Totaro, and M. Amato
Subjects: multiple sclrosis, pregnancy, drug exposure
Published: 2014

10. A comparison of the brief International cognitive assessment for multiple sclerosis and the brief repeatable battery in multiple sclerosis patients

Author: E. Portaccio, B. Goretti, C. Niccolai, B. Hakiki, M. Giannini, L. Pastò, C. Pecori, F. Razzolini, M. Falautano, E. Minacapelli, V. Martinelli, C. Incerti, U. Nocentini, M. Murgia, G. Fenu, E. Cocco, M. Marrosu, E. Garofalo, F. Ambra, M. Maddestra, M. Consalvo, R. Viterbo, M. Trojano, N. Losignore, G. Zimatore, E. Pietrolongo, LUGARESI, ALESSANDRA, L. Pippolo, M. Roscio, A. Ghezzi, D. Castellano, S. Stecchi, M. Amato, E. Portaccio, B. Goretti, C. Niccolai, B. Hakiki, M. Giannini, L. Pastò, C. Pecori, F. Razzolini, M. Falautano, E. Minacapelli, V. Martinelli, C. Incerti, U. Nocentini, M. Murgia, G. Fenu, E. Cocco, M. Marrosu, E. Garofalo, F. Ambra, M. Maddestra, M. Consalvo, R. Viterbo, M. Trojano, N. Losignore, G. Zimatore, E. Pietrolongo, A. Lugaresi, L. Pippolo, M. Roscio, A. Ghezzi, D. Castellano, S. Stecchi, and M. Amato
Subjects: multiple sclerosis, cognition, tests, cognitive battery
Published: 2014

11. A comparison of the Brief International Cognitive Assessment for Multiple Sclerosis and a brief repeatable battery in multiple sclerosis patients

Author: E. Portaccio, B. Goretti, C. Niccolai, B. Hakiki, M. iannini, L. Pastò, C. Pecori, L. Razzolini, M. Falautano, E. Minacapelli, V. Martinelli, C. Incerti, U. Nocentini, M. Murgia, G. Fenu, E. Cocco, MG Marrosu, E. Garofalo, FI Ambra, M. Maddestra, M. Consalvo, RG Viterbo, M. Trojano, NA Losignore, GB Zimatore, E. Pietrolongo, LUGARESI, ALESSANDRA, L. Pippolo, M. Roscio, A. Ghezzi, D. Castellano, S. Stecchi, MP Amato, E. Portaccio, B. Goretti, C. Niccolai, B. Hakiki, M. iannini, L. Pastò, C. Pecori, L. Razzolini, M. Falautano, E. Minacapelli, V. Martinelli, C. Incerti, U. Nocentini, M. Murgia, G. Fenu, E. Cocco, MG Marrosu, E. Garofalo, FI Ambra, M. Maddestra, M. Consalvo, RG Viterbo, M. Trojano, NA Losignore, GB Zimatore, E. Pietrolongo, A. Lugaresi, L. Pippolo, M. Roscio, A. Ghezzi, D. Castellano, S. Stecchi, and MP Amato.
Subjects: multiple sclerosis, cognition, evaluation
Published: 2014

12. Comparison of fingolimod versus interferon-beta/glatiramer acetate as second-line therapy in active multiple sclerosis

Author: A. He, T. Spelman, V. Jokubaitis, LUGARESI, ALESSANDRA, G. Izquiero, M. Trojano, P. Grammond, J. Lechner Scott, P. Duquette, M. Girard, E. Pucci, M. Slee, F. Grand’Maison, C. . Oreja Guevara, C. Boz, R. Fernandez Bolanos, S. Hodgkinson, J. Sanchez Menoyo, G. Iuliano, M. Barnett, F. Moore, H. Butzkueven, T. Kalincik, Ms Base Study Group, A. He, T. Spelman, V Jokubaiti, A. Lugaresi, G. Izquiero, M. Trojano, P. Grammond, J. Lechner-Scott, P. Duquette, M. Girard, E. Pucci, M. Slee, F. Grand’Maison, C . Oreja-Guevara, C. Boz, R. Fernandez-Bolano, S. Hodgkinson, J. Sanchez-Menoyo, G. Iuliano, M. Barnett, F. Moore, H. Butzkueven, T. Kalincik, and Ms Base Study Group.
Subjects: multiple sclerosis,interferom beta, glatiramer acetate, fingolimod, efficacy
Published: 2014

13. Seasonal variation of relapse rate in MS is latitude-dependent

Author: T. Spelman, O. Gray, M. Trojano, T. Petersen, G. Izquierdo, R. Hupperts, R. Bergamaschi, P. Duquette, P. Grammond, G. Giuliani, C. Boz, F. Verheul, C. Oreja Guevara, M. Banett, F. Grand’Maison, H. Butzkueven, on behalf of the MSBase Investigators, LUGARESI, ALESSANDRA, T. Spelman, O. Gray, M. Trojano, T. Petersen, G. Izquierdo, A. Lugaresi, R. Huppert, R. Bergamaschi, P. Duquette, P.Grammond, G. Giuliani, C. Boz, F. Verheul, C. Oreja-Guevara, M. Banett, F. Grand’Maison, H. Butzkueven, and on behalf of the MSBase Investigators.
Subjects: multiple sclerosis, latitude, relapses
Published: 2014

14. Indipendent predictors of time to relapse after CIS in high-risk patients

Author: T. Spelman, C. Meyniel, M. Trojano, LUGARESI, ALESSANDRA, G. Izquierdo, F. Grand’Maison, C. Boz, L. Alroughani, E. Havvrdova, G. Iuliano, P. Duquette, M. Terzi, P. Grammond, J.A. Cabrera Gomez, R. Hupperts, J. Lechner Scott, H. Butzkueven, T. Spelman, C. Meyniel, M. Trojano, A. Lugaresi, G. Izquierdo, F. Grand’Maison, C. Boz, L. Alroughani, E. Havvrdova, G. Iuliano, P. Duquette, M. Terzi, P. Grammond, JA. Cabrera-Gomez, R. Huppert, J. Lechner-Scott, and H. Butzkueven
Subjects: Multiple sclerosis, prognosis, clinically isolated syndrome
Published: 2014

15. Long term results of natalizumb in the treatment of pediatric MS patients

Author: A. Ghezzi, C. Pozzilli, L. Moiola, V. Brescia Morra, F. Bortolon, R. Capra, G. Coniglio, M. Filippi, C. Gasperini, L. Grimaldi, R. Lanzillo, G. Lus, LUGARESI, ALESSANDRA, N. Milani, L. Prosperini, L. Provinciali, E. Pucci, F. rinaldi, M. Rocca, M. Rottoli, P. Sarchielli, M. Trojano, A. Bianchi, G. Comi, A. Ghezzi, C. Pozzilli, L. Moiola, V. Brescia Morra, F. Bortolon, R. Capra, G. Coniglio, M. Filippi, C. Gasperini, L. Grimaldi, R. Lanzillo, G. Lu, A. Lugaresi, N. Milani, L. Prosperini, L. Provinciali, E. Pucci, F. rinaldi, M. Rocca, M. Rottoli, P. Sarchielli, M. Trojano, A. Bianchi, and G. Comi
Subjects: multiple sclerosis, pediatric, natalizumab, treatment
Published: 2014

16. THC:CBD Daily Practice Evidence in MS Spasticity Management: The Moment of Large Databases

Author: M. Trojano
Subjects: Moment (mathematics), Medical education, Geography, Operations research, Multiple sclerosis, Daily practice, medicine, Spasticity, medicine.symptom, medicine.disease
Published: 2016

17. Symptomatology of multiple sclerosis relapses varies in relation to demographic and clinical factors

Author: T. Kalincik, K. Buzzard, M. Trojano, P. Duquette, M. Girard, G. Izquierdo, P. Grammond, LUGARESI, ALESSANDRA, T. Petersen, R. Hupperts, R. Bergamaschi, C. Boz, G. Giuliani, M. Barnett, J. Lechner Scott, F. Grand’Maison, C. Oreja Guevara, G. Iuliano, M. Amato, F. Verheul, E. Cristiano, R. Fernandez Bolanos, V. Van Pesch, M. Fiol, M. Rio, M. Slee, S. Flechter, O. Gray, M. Saladino, D. La Spitaleri, J. Cabrera Gomez, M. Paine, C. Shaw, R. Alroughani, N. Vella, C. Rozsa, S. Vucic, F. Moore, B. Singhal, N. Deri, M. Needham, V. Santiago, J. Herbert, A. Savino, C. Sirbu, T. Petkovska Boskova, E. Bacile Bacile, V. Jokubaitis, D. Liew, H. Butzkueven on behalf of the MSBase Study Group, T. Kalincik, K. Buzzard, M. Trojano, P. Duquette, M. Girard, G. Izquierdo, P. Grammond, A. Lugaresi, T. Petersen, R. Huppert, R. Bergamaschi, C. Boz, G. Giuliani, M. Barnett, J. Lechner-Scott, F. Grand’Maison, C. Oreja-Guevara, G. Iuliano, M. Amato, F. Verheul, E. Cristiano, R. Fernandez-Bolano, V. Van Pesch, M. Fiol, M. Rio, M. Slee, S. Flechter, O. Gray, M. Saladino, D. La Spitaleri, J. Cabrera-Gomez, M. Paine, C. Shaw, R. Alroughani, N. Vella, C. Rozsa, S. Vucic, F. Moore, B. Singhal, N. Deri, M. Needham, V. Santiago, J. Herbert, A. Savino, C. Sirbu, T. Petkovska-Boskova, E. Bacile Bacile, V. Jokubaiti, D. Liew, and H. Butzkueven on behalf of the MSBase Study Group.
Subjects: multiple sclerosis, demographic characteristics, symptoms
Published: 2013

18. Well-being and health-related quality of life among persons with multiple sclerosis, caregivers and health professionals: a comparative study

Author: M. Bassi, E. Pietrolongo, M. Falautano, S. Cilia, B. Goretti, M. Grobberio, M. Pattini, R. G. Viterbo, M. P. Amato, LUGARESI, ALESSANDRA, V. Martinelli, E. Montanari, F. Patti, M. Trojano, A. Delle Fave, M. Bassi, E. Pietrolongo, M. Falautano, S. Cilia, B. Goretti, M. Grobberio, M. Pattini, R.G. Viterbo, M.P. Amato, A. Lugaresi, V. Martinelli, E. Montanari, F. Patti, M. Trojano, and A. Delle Fave
Subjects: multiple sclerosis, patient related outcomes
Published: 2013

19. Observational case-control study of the prevalence of chronic cerebrospinal venous insufficiency in multiple sclerosis: results from the CoSMo study

Author: G. Comi, M. Battaglia, A. Bertolotto, M. D. Sette, A. Ghezzi, G. Malferrari, M. Salvetti, M. Sormani, L. Tesio, E. Stolz, P. Zaratin, G. Mancardi, A. CoSMo Collaborative Study group [, A. Protti, A. Ciuffoli, A. Bratina, A. Guccione, A. Deboni, B. Giometto, C. Finocchi, C. Baracchini, D. Maimone, D. Rossato, D. Centonze, D. Ciampanelli, E. Favaretto, E. Menci, E. Granieri, E. Sanzaro, F. Viaro, F. Bortolon, F. Iemolo, F. Patti, F. Tezzon, G. Costantino, G. L. Mancardi, G. Sette, G. M. Nuzzaco, L. Provinciali, L. Coppo, L. D. Maggio, L. Monti, L. Pascazio, L. Grimaldi, L. Motti, M. Mancini, M. Busso, M. Rovaris, M. Buccafusca, M. L. Zedde, M. R. Tola, M. Trojano, M. Spinelli, M. Stefanini, M. Cirrito, M. Ulivelli, N. Carraro, N. D. Rossi, P. Cavalla, P. Gallo, P. Lochner, P. Cecconi, R. Mantegazza, R. Gaeta, R. Bergamaschi, R. Capra, S. Cottone, S. Sanguigni, S. Stecchi, S. Grazioli, S. Tonello, V. B. Morra], LUGARESI, ALESSANDRA, Comi, G, Battaglia, Ma, Bertolotto, A, Del Sette, M, Ghezzi, A, Malferrari, G, Salvetti, M, Sormani, Mp, Tesio, L, Stolz, E, Zaratin, P, Mancardi, G, BRESCIA MORRA, Vincenzo, CoSMo COllaborative Study, Group, Giometto, B, G. Comi, M. Battaglia, A. Bertolotto, M. D. Sette, A. Ghezzi, G. Malferrari, M. Salvetti, M. Sormani, L. Tesio, E. Stolz, P. Zaratin, G. Mancardi, A. CoSMo Collaborative Study group [, Alessandra Lugaresi, A. Protti, A. Ciuffoli, A. Bratina, A. Guccione, A. Deboni, B. Giometto, C. Finocchi, C. Baracchini, D. Maimone, D. Rossato, D. Centonze, D. Ciampanelli, E. Favaretto, E. Menci, E. Granieri, E. Sanzaro, F. Viaro, F. Bortolon, F. Iemolo, F. Patti, F. Tezzon, G. Costantino, G. L. Mancardi, G. Sette, G. M. Nuzzaco, L. Provinciali, L. Coppo, L. D. Maggio, L. Monti, L. Pascazio, L. Grimaldi, L. Motti, M. Mancini, M. Busso, M. Rovari, M. Buccafusca, M. L. Zedde, M. R. Tola, M. Trojano, M. Spinelli, M. Stefanini, M. Cirrito, M. Ulivelli, N. Carraro, N. D. Rossi, P. Cavalla, P. Gallo, P. Lochner, P. Cecconi, R. Mantegazza, R. Gaeta, R. Bergamaschi, R. Capra, S. Cottone, S. Sanguigni, S. Stecchi, S. Grazioli, S. Tonello, V. B. Morra], Comi, Giancarlo, and CoSMo Collaborative Study, Group
Subjects: Adult, Brain, blood supply, Case-Control Studies, Female, Humans, Male, Middle Aged, Multiple Sclerosis, complications/epidemiology, Prevalence, Spinal Cord, blood supply, Venous Insufficiency, complications/epidemiology, Adult, Male, medicine.medical_specialty, Pediatrics, Neurology, Chronic cerebrospinal venous insufficiency, multicentric study, multiple sclerosis, neurodegenerative disease, Prevalence, medicine, Humans, circulatory system, sonography, Chronic cerebrospinal venous insufficiency, Italy, circulatory system, multicentric study, multiple sclerosis, neurodegenerative disease, prevalence study, sonography, business.industry, Multiple sclerosis, prevalence study, Case-control study, Brain, Middle Aged, medicine.disease, blood supply, Surgery, Spinal Cord, Venous Insufficiency, Italy, Case-Control Studies, multiple sclerosi, Duplex sonography, Female, Observational study, Settore MED/26 - Neurologia, Neurology (clinical), business
Abstract: Background: Chronic cerebrospinal venous insufficiency (CCSVI) has been proposed as a possible cause of multiple sclerosis (MS). Objectives: The CoSMo study evaluated the association between CCSVI and MS. Methods: The primary end-point of this multicentric, case-control study was to compare the prevalence of CCSVI between patients with MS, patients with other neurodegenerative diseases (ONDs) and healthy controls (HCs). Color-coded duplex sonography was performed by a sonologist and the images were sent to one of three central sonologists for a second reading. Agreement between local and central sonologists or, in case of disagreement, the predominant judgment among the three central readers, was required for a diagnosis of CCSVI. All readings, data collection and analysis were blinded. Results: The study involved 35 MS centers across Italy and included 1874 subjects aged 18–55. 1767 (94%) were evaluable: 1165 MS patients, 226 patients with ONDs and 376 HCs. CCSVI prevalence was 3.26%, 3.10% and 2.13% for the MS, OND and HC groups, respectively. No significant difference in CCSVI prevalence was found amongst the three cohorts (MS versus HC, OR = 1.55, 95%CI = 0.72–3.36, p = 0.30; OND versus HC, OR = 1.47, 95%CI = 0.53–4.11, p = 0.46; MS versus OND, OR = 1.05, 95%CI = 0.47–2.39, p = 0.99). High negative and low positive agreement was found between the local and centralized readers. Conclusions: CCSVI is not associated with MS.
Published: 2013

20. The brief international cognitive assessment for multiple sclerosis (bicams): normative values in the Italian population

Author: B. Hakiki, E. Portaccio, C. Niccolai, B. Goretti, V. Martinelli, M. Falautano, E. Minacapelli, U. Nocentini, C. Incerti, M. Marrosu, E. Cocco, M. Murgia, G. Fenu, F. Ambra, E. Garofalo, M. Maddestra, M. Consalvo, G. Zimatore, N. Losignore, LUGARESI, ALESSANDRA, E. Pietrolongo, R. Viterbo, M. Trojano, M. Amato, B. Hakiki, E. Portaccio, C. Niccolai, B. Goretti, V. Martinelli, M.Falautano, E. Minacapelli, U. Nocentini, C. Incerti, M. Marrosu, E.Cocco, M. Murgia, G. Fenu, F. Ambra, E. Garofalo, M. Maddestra, M. Consalvo, G. Zimatore, N. Losignore, A. Lugaresi, E. Pietrolongo, R. Viterbo, M. Trojano, and M. Amato
Subjects: multiple sclerosis, neuropsychological testing
Published: 2013

21. Endovascular treatment of CCSVI in patients with multiple sclerosis: clinical outcome of an italian cohort of 462 cases

Author: A. Ghezzi, P. O. Annovazzi, M. P. Amato, R. Balghera, P. Banfi, M. L. Bartolozzi, R. Bergamaschi, A. Bertolotto, A. Bianchi, A. Bosco, E. Capello, M. Capobianco, R. Capra, P. Cavalla, R. Clerici, G. Coarelli, E. Cocco, N. De Rossi, C. Di Tillio, M. T. Ferrò, A. Gallo, P. Gallo, L. Lamantia, LUGARESI, ALESSANDRA, G. Lus, S. Malucchi, L. Moiola, L. Provinciali, F. Patti, P. Perini, P. Perrone, A. Protti, M. E. Rodegher, P. Rossi, M. Rottoli, M. Rovaris, G. Salemi, M. Salvetti, I. Simeone, M. R. Tola, M. Trojano, F. Vitetta, M. G. Marrosu, G. Comi, MS Study Group, Italian Society of Neurology, A. Ghezzi, P.O. Annovazzi, M.P. Amato, R. Balghera, P. Banfi, M.L. Bartolozzi, R. Bergamaschi, A. Bertolotto, A. Bianchi, A. Bosco, E. Capello, M. Capobianco, R. Capra, P. Cavalla, R. Clerici, G. Coarelli, E. Cocco, N. De Rossi, C. Di Tillio, M.T. Ferrò, A. Gallo, P. Gallo, L. Lamantia, A. Lugaresi, G. Lu, S. Malucchi, L. Moiola, L. Provinciali, F. Patti, P. Perini, P. Perrone, A. Protti, M.E. Rodegher, P. Rossi, M. Rottoli, M. Rovari, G. Salemi, M. Salvetti, I. Simeone, M.R. Tola, M. Trojano, F. Vitetta, M.G. Marrosu, G. Comi and MS Study Group, and Italian Society of Neurology
Subjects: multiple sclerosis, treatment, venous circulation, angioplasty, safety
Published: 2012

22. Male MS patients fare worse!

Author: K. A. Ribbons, P. McElduff, S. Vetere, C. Boz, M. Trojano, C. Zwanikken, LUGARESI, ALESSANDRA, G. Izquierdo, P. Duquette, M. Girard, F. Grand‘Maison, P. Grammond, C. Oreja Guevara, R. Hupperts, T. Petersen, R. Bergamaschi, G. Guiliani, M. Barnett, V. Van Pesch, M. P. Amato, G. Iuliano, M. Fiol, M. Slee, F. Verheul, E. Cristiano, R. Fernandez Bolanos, M. L. Saladino, M. E. Rio, W. Oleschko Arruda, J. Cabrera Gomez, M. Paine, N. Vella, C. Shaw, F. Moore, S. Vucic, T. Petkovska Boskova, H. Butzkueven, J. S. Lechner Scott on behalf of the MS Base Group, K.A. Ribbon, P. McElduff, S. Vetere, C. Boz, M. Trojano, C. Zwanikken, A. Lugaresi, G. Izquierdo, P. Duquette, M. Girard, F. Grand‘Maison, P. Grammond, C. Oreja-Guevara, R. Huppert, T. Petersen, R. Bergamaschi, G. Guiliani, M. Barnett, V. Van Pesch, M.P. Amato, G. Iuliano, M. Fiol, M. Slee, F. Verheul, E. Cristiano, R. Fernandez-Bolano, M.L. Saladino, M.E. Rio, W. Oleschko Arruda, J. Cabrera-Gomez, M. Paine, N. Vella, C. Shaw, F. Moore, S. Vucic, T. Petkovska-Boskova, H. Butzkueven, and J.S. Lechner-Scott on behalf of the MS Base Group.
Subjects: multiple sclerosis, prognosis, gender
Published: 2012

23. The 'Sapere Migliora' information aid for newly-diagnosed MS patients: developing and testing phases following the MRC framework

Author: A. Solari, A. Giordano, V. Martinelli, F. Granella, P. Confalonieri, M. Trojano, M. Messmer Uccelli, C. Borreani, The Sims Project, LUGARESI, ALESSANDRA, A. Solari, A. Giordano, A. Lugaresi, V. Martinelli, F. Granella, P. Confalonieri, M. Trojano, M. Messmer Uccelli, C. Borreani, and The Sims Project
Subjects: multiple sclerosis, information aid
Published: 2012

24. The Care system: well-being promotion among people with multiple sclerosis, caregivers and health professionals

Author: M. Bassi, M. Falautano, S. Cilia, B. Goretti, M. Grobberio, M. Pattini, E. Pietrolongo, R. Viterbo, M. Amato, LUGARESI, ALESSANDRA, V. Martinelli, E. Montanari, F. Patti, M. Trojano, A. Delle Fave, M. Bassi, M. Falautano, S. Cilia, B. Goretti, M. Grobberio, M. Pattini, E. Pietrolongo, R. Viterbo, M. Amato, A. Lugaresi, V. Martinelli, E. Montanari, F. Patti, M. Trojano, and A. Delle Fave
Subjects: multiple sclerosis, mental health, physical health, caregiver, health professional
Published: 2012

25. Increased risk of disability progression after pregnancy in MS patients with active disease

Author: E. Portaccio, A. Ghezzi, B. Hakiki, L. Pastò, M. Giannini, L. Razzolini, V. Martinelli, L. Moiola, F. Patti, L. La Mantia, G. Mancardi, C. Solaro, M. Tola, C. Pozzilli, L. De Giglio, R. Totaro, LUGARESI, ALESSANDRA, V. Di Tommaso, D. Paolicelli, M. Marrosu, G. Comi, M. Trojano, M. Amato, . the MS study group of the Italian Neurological Society, E. Portaccio, A. Ghezzi, B. Hakiki, L. Pastò, M. Giannini, L. Razzolini, V. Martinelli, L. Moiola, F. Patti, L. La Mantia, G. Mancardi, C. Solaro, M.Tola, C. Pozzilli, L. De Giglio, R. Totaro, A. Lugaresi, V. Di Tommaso, D. Paolicelli, M. Marrosu, G. Comi, M. Trojano, M. Amato, and the MS study group of the Italian Neurological Society
Subjects: multiple sclerosis, pregnancy, treatment discontinuation, prognosis
Published: 2012

26. The effect of pregnancy on relapse rate and disability progression in MS: results from the MSBase Registry

Author: S. E. Hughes, T. Spelman, O. M. Gray, C. Boz, M. Trojano, C. Zwanikken, LUGARESI, ALESSANDRA, G. Izquierdo, P. Duquette, M. Girard, F. Grand’Maison, P. Grammond, C. Oreja Guevara, R. Hupperts, T. Petersen, R. Bergamaschi, G. Giuliani, J. Lechner Scott, M. Barnett, M. Edite Rio, V. van Pesch, M. P. Amato, G. Iuliano, M. Fiol, M. Slee, F. Verheul, E. Cristiano, R. Fernández Bolaños, D. Poehlau, M. Saladino, N. Deri, W. Oleschko Arruda, J. A. Cabrera Gomez, M. Paine, N. Vella, J. Herbert, E. Skromne, A. Savino, C. Shaw, F. Moore, S. Vucic, T. Petkovska Boskova, V. Santiago, H. Butzkueven on behalf of the MSBase Study Group, S.E. Hughe, T. Spelman, O.M. Gray, C. Boz, M. Trojano, C. Zwanikken, A. Lugaresi, G. Izquierdo, P. Duquette, M. Girard, F. Grand’Maison, P. Grammond, C. Oreja-Guevara, R. Huppert, T. Petersen, R. Bergamaschi, G. Giuliani, J. Lechner-Scott, M. Barnett, M. Edite Rio, V. van Pesch, M.P. Amato, G. Iuliano, M. Fiol, M. Slee, F. Verheul, E. Cristiano, R. Fernández Bolaño, D. Poehlau, M. Saladino, N. Deri, W. Oleschko Arruda, J.A. Cabrera-Gomez, M. Paine, N. Vella, J. Herbert, E. Skromne, A. Savino, C. Shaw, F. Moore, S. Vucic, T. Petkovska-Boskova, V. Santiago, and H. Butzkueven on behalf of the MSBase Study Group
Subjects: multiple sclerosis, prognosis, pregnancy, disability
Published: 2011

27. Predictors of post-partum relapses and disability progression in Multiple Sclerosis

Author: E. Portaccio, A. Ghezzi, B. Hakiki, M. Giannini, L. Pastò, L. Razzolini, V. Martinelli, L. Moiola, F. Patti, L. La Mantia, G. Mancardi, C. Solaro, M. Tola, C. Pozzilli, L. De Giglio, R. Totaro, LUGARESI, ALESSANDRA, V. Di Tommaso, D. Paolicelli, M. Marrosu, G. Comi, M. Trojano, M. Amato for the MS study group of the Italian Neurological Society, E. Portaccio, A. Ghezzi, B. Hakiki, M. Giannini, L. Pastò, L. Razzolini, V. Martinelli, L. Moiola, F. Patti, L. La Mantia, G. Mancardi, C. Solaro, M. Tola, C. Pozzilli, L. De Giglio, R. Totaro, A. Lugaresi, V. Di Tommaso, D. Paolicelli, M. Marrosu, G. Comi, M. Trojano, and M. Amato for the MS study group of the Italian Neurological Society
Subjects: multiple sclerosis, prognosi, pregnancy, puerperium, relapses
Published: 2011

28. Epidural analgesia and caesarean delivery are not associated with post-partum relapses and disability in MS

Author: L. Pastò, E. Portaccio, A. Ghezzi, B. Hakiki, M. Giannini, L. Razzolini, L. De Giglio, C. Pozzilli, D. Paolicelli, M. Trojano, M. Marrosu, F. Patti, L. La Mantia, G. Mancardi, C. Solaro, R. Totaro, M. Tola, V. Di Tommaso, LUGARESI, ALESSANDRA, L. Moiola, V. Martinelli, G. Comi, M. Amato, For The MS Study Group of the Italian Neurological Society, L. Pastò, E. Portaccio, A. Ghezzi, B. Hakiki, M. Giannini, L. Razzolini, L. De Giglio, C. Pozzilli, D. Paolicelli, M. Trojano, M. Marrosu, F. Patti, L. La Mantia, G. Mancardi, C. Solaro, R. Totaro, M. Tola, V. Di Tommaso, A. Lugaresi, L. Moiola, V. Martinelli, G. Comi, M. Amato, and For The MS Study Group of the Italian Neurological Society
Subjects: multiple sclerosis, partum, analgesia, delivery
Published: 2011

29. Pregnancy and fetal outcomes after Glatiramer acetate exposure in patients with Multiple Sclerosis

Author: M. Giannini, E. Portaccio, A. Ghezzi, B. Hakiki, L. Pastò, L. Razzolini, L. De Giglio, C. Pozzilli, D. Paolicelli, M. Trojano, M. Marrosu, F. Patti, L. La Mantia, G. Mancardi, C. Solaro, R. Totaro, M. Tola, V. Di Tommaso, LUGARESI, ALESSANDRA, L. Moiola, V. Martinelli, G. Comi, M. Amato, for the MS study group of the Italian Neurological Society, M. Giannini, E. Portaccio, A. Ghezzi, B. Hakiki, L. Pastò, L. Razzolini, L. De Giglio, C. Pozzilli, D. Paolicelli, M. Trojano, M. Marrosu, F. Patti, L. La Mantia, G. Mancardi, C. Solaro, R. Totaro, M. Tola, V. Di Tommaso, A. Lugaresi, L. Moiola, V. Martinelli, G. Comi, M. Amato, and for the MS study group of the Italian Neurological Society
Subjects: pregnancy, glatiramer acetate, multiple sclerosis, treatment, safety
Published: 2011

30. Real-life impact of early interferonβ therapy in relapsing multiple sclerosis

Author: M. TROJANO, F. PELLEGRINI, D. PAOLICELLI, A. FUIANI, GB ZIMATORE, C. TORTORELLA, IL SIMONE, F, PATTI, A. GHEZZI, E. PORTACCIO, P. ROSSI, C. POZZILLI, G. SALEMI, A. LUGARESI, R. BERGAMASCHI, E, MILLEFIORINI, M. CLERICO, M. VIANELLO, C. AVOLIO, P. CAVALLA, V. LEPORE, P. LIVREA, G. COMI, MP AMATO, LUS, Giacomo, M., Trojano, F., Pellegrini, D., Paolicelli, A., Fuiani, Gb, Zimatore, C., Tortorella, Il, Simone, F, Patti, A., Ghezzi, E., Portaccio, P., Rossi, C., Pozzilli, G., Salemi, A., Lugaresi, R., Bergamaschi, E, Millefiorini, M., Clerico, Lus, Giacomo, M., Vianello, C., Avolio, P., Cavalla, V., Lepore, P., Livrea, G., Comi, and Mp, Amato
Published: 2009

31. Challenges in the MS Patient Overall Management

Author: X. Montalbn and M. Trojano
Subjects: geography, Summit, geography.geographical_feature_category, Operations research, Library science
Published: 2014

32. The Real Life Impact of Early Versus Delayed Treatment of Interferon beta on Long-Term Disability Progression in Relapsing-Remitting Multiple Sclerosis

Author: M. Trojano, M. P. Amato, C. Avolio, R. Bergamaschi, P. Cavalla, L. Durelli, A. Fuiani, A. Ghezzi, G. Lus, E. Millefiorini, D. Paolicelli, F. Patti, F. Pellegrini, C. Pozzilli, P. Rossi, G. Salemi, M. Vianello, P. Livrea, G. Comi, LUGARESI, ALESSANDRA, M. Trojano, M. P. Amato, C. Avolio, R. Bergamaschi, P. Cavalla, L. Durelli, A. Fuiani, A. Ghezzi, A. Lugaresi, G. Lu, E. Millefiorini, D. Paolicelli, F. Patti, F. Pellegrini, C. Pozzilli, P. Rossi, G. Salemi, M. Vianello, P. Livrea, and G Comi
Subjects: multiple sclerosis, treatment, early, late
Published: 2008

33. Blood Brain Barrier (BBB) Impairment in NMO-IgG Seropositive Patients: An Aquaporine-4 (AQP-4) Related Damage?

Author: C. Tortorella, M. Ruggieri, G. B. Zimatore, A. Frigeri, A. L., E. Di Monte, A. Ghezzi, A. Rizzo, M. P. Amato, B. Hakiki, F. Patti, LUGARESI, ALESSANDRA, E. Merelli, P. Livrea, M. Svelto, M. Trojano, C. Tortorella, M. Ruggieri, G. B. Zimatore, A. Frigeri, A. L., E. Di Monte, A. Ghezzi, A. Rizzo, M. P. Amato, B. Hakiki, F. Patti, A. Lugaresi, E. Merelli, P. Livrea, M. Svelto, and M. Trojano.
Subjects: neuromyelitis optica, blood-brain-barrier, IgG-NMO
Published: 2008

34. Heterogeneous impact of an early IFN-beta treatment on disability progression in Relapsing MS subgroups with different baseline clinical profiles

Author: M. TROJANO, MP AMATO, C. AVOLIO, R. BERGAMASCHI, P. CAVALLA, L. DURELLI, A. FUIANI, A. GHEZZI, G. GIULIANI, A. LUGARESI, E. MILLEFIORINI, D. PAOLICELLI, F. PATTI, F. PELLEGRINI, C. POZZILLI, P. ROSSI, G. SALEMI, M. VIANELLO, G. COMI ON BEHALF OF ITALIAN MULTIPLE SCLEROSIS DATABASE NETWORK MSDN GROUP, LUS, Giacomo, M., Trojano, Mp, Amato, C., Avolio, R., Bergamaschi, P., Cavalla, L., Durelli, A., Fuiani, A., Ghezzi, G., Giuliani, A., Lugaresi, Lus, Giacomo, E., Millefiorini, D., Paolicelli, F., Patti, F., Pellegrini, C., Pozzilli, P., Rossi, G., Salemi, M., Vianello, and G., COMI ON BEHALF OF ITALIAN MULTIPLE SCLEROSIS DATABASE NETWORK MSDN GROUP
Published: 2007

35. Multiple sclerosis in twins from continental Italy and Sardinia: a nationwide study

Author: Ristori G, Cannoni S, Stazi MA, Vanacore N, Cotichini R, Alfo M, Pugliatti M, Sotgiu S, Solaro C, Bomprezzi R, Di Giovanni S, Figa` Talamanca L, Nistico L, Fagnani C, Neale MC, Cascino I, Giorgi G, Battaglia MA, Buttinelli C, Tosi R, Salvetti M, M. Melato, R. Dellantonio, L. Sironi, E. Bottacchi, M. Signorino, R. Angeloni, L. Curatola, C. Paci, M. Ragno, G. Sirocchi, AM. Vurchio, E. Duc, D. Spitaleri, M. Trojano, M. Liguori, N. Cimini, G. Moretto, M. Porta, MR Rottoli A. Mamoli, M. Camerlingo, E. Nardozza, T. Sacquegna, S. Stecchi, C. Scandellari, L. Callea, R. Capra, M. Codella, M. G. Marrosu, E. Cocco, A. Spissu, G. Cossu, S. Tronci, A. Di Lauro, E. Lombardi, A. Reggio, F. Patti, P. Valentino, A. Quattrone, D Farina, M. E. Nives, A. Lugaresi, F. Perla, M. G. Rosso, M. R. Tola, E. Granieri, MP Amato L. Massacesi, E. Millefiorini, V. Durastanti, G. L. Mancardi, A. Murialdo, NR. Pizio, P. Bellantonio, R. Fantozzi, R. Totaro, A. Carolei, F. Giramma, A. T. Lazzaro, C. Giraldi, M. Mazzoni, G. Giuliani, E. Pucci, P. Previdi, MC. Fazio, M. Buccafusca, P. Girlanda, C. Messina, G. D’Aleo, C. Milanese, L. Lamantia, D. Caputo, E. Scarpini, R. Clerici, L. Moiola, M. Gironi, E. Merelli, F. Casoni, S. Bonavita, G. Tedeschi, M. Leone, D. Mittino, SB. Murgia, L. Musu, P. Gallo, P. Perini, E. Frasson, G. Salemi, G. Cuccia, E. Montanari, L. Manneschi, D. Saviola, M. Antonelli, V. Cosi, R. Bergamaschi, V. Gallai, D. Murasecco, P. Sarchielli, R. Urcioli, G. Perticoni, G. Meucci, G. Moscato, B. Lucci, E. Covezzi, MG. Coniglio, D. Acquistapace, L. Motti, B. Dossi Curro`, M. Frontoni, C. Mainero, P. Giannetti, I. Pestalozza, S. Di Legge, M. Spadaro, C. Pozzilli, S. Romano, B. Mercuri, C. Scoppetta, C. Gasperini, S. Galgani, MG. Grasso, S. Paolucci, PA. Tonali, A. Leonardi, A. Oneto, G Rosati, M. A. Sotgiu, A. Bertolotto, M. Capobianco, L. Durelli, M. Clerico, L. Sosso, R. Bongioanni, D. Orrico, C. Carbonin, U. Freo. M. Zaffaroni, A. Ghezzi, N. Falcone, Ristori G, Cannoni S, Stazi MA, Vanacore N, Cotichini R, Alfo M, Pugliatti M, Sotgiu S, Solaro C, Bomprezzi R, Di Giovanni S, Figa` Talamanca L, Nistico L, Fagnani C, Neale MC, Cascino I, Giorgi G, Battaglia MA, Buttinelli C, Tosi R, Salvetti M, M. Melato, R. Dellantonio, L.Sironi, E. Bottacchi, M. Signorino, R. Angeloni, L. Curatola, C. Paci, M. Ragno, G. Sirocchi, AM. Vurchio, E. Duc, D. Spitaleri, M. Trojano, M. Liguori, N. Cimini, G. Moretto, M. Porta, MR Rottoli A. Mamoli, M. Camerlingo, E. Nardozza, T. Sacquegna, S. Stecchi, C. Scandellari, L. Callea, R. Capra, M. Codella, M. G. Marrosu, E. Cocco, A. Spissu, G. Cossu, S. Tronci, A. Di Lauro, E. Lombardi, A. Reggio, F. Patti, P. Valentino, A. Quattrone, D Farina, M. E. Nives, A. Lugaresi, F. Perla, M. G. Rosso, M.R. Tola, E. Granieri, MP Amato L. Massacesi, E. Millefiorini, V. Durastanti, G. L. Mancardi, A. Murialdo, NR. Pizio, P. Bellantonio, R. Fantozzi, R. Totaro, A. Carolei, F. Giramma, A. T. Lazzaro, C. Giraldi, M. Mazzoni, G. Giuliani, E. Pucci, P. Previdi, MC. Fazio, M. Buccafusca, P. Girlanda, C. Messina, G. D’Aleo, C. Milanese, L. Lamantia, D. Caputo, E. Scarpini, R. Clerici, L. Moiola, M. Gironi, E. Merelli, F. Casoni, S. Bonavita, G. Tedeschi, M. Leone, D. Mittino, SB. Murgia, L. Musu, P. Gallo, P. Perini, E. Frasson, G. Salemi, G. Cuccia, E. Montanari, L. Manneschi, D. Saviola, M. Antonelli, V. Cosi, R. Bergamaschi, V. Gallai, D. Murasecco, P. Sarchielli, R. Urcioli, G. Perticoni, G. Meucci, G. Moscato, B. Lucci, E. Covezzi, MG. Coniglio, D. Acquistapace, L. Motti, B. Dossi Curro`, M. Frontoni, C. Mainero, P. Giannetti, I. Pestalozza, S. Di Legge, M. Spadaro, C. Pozzilli, S. Romano, B. Mercuri, C. Scoppetta, C. Gasperini, S. Galgani, MG. Grasso, S. Paolucci, PA. Tonali, A. Leonardi, A. Oneto, and G Rosati, M. A. Sotgiu, A. Bertolotto, M. Capobianco, L. Durelli, M. Clerico, L. Sosso, R. Bongioanni, D. Orrico, C. Carbonin, U. Freo. M. Zaffaroni, A. Ghezzi, N. Falcone
Subjects: Male, Questionnaires, Multiple Sclerosis, Concordance, Population, Twins, Dizygotic twins, Disease cause, Multiple Sclerosis, Epidemiology, Twins, Cohort Studies, Cohort Studies, Disease Susceptibility, Female, Genetic Predisposition to Disease, Humans, Italy, epidemiology, Male, Multiple Sclerosis, epidemiology/genetics, Questionnaires, Regression Analysis, Twins, Surveys and Questionnaires, medicine, Humans, Genetic Predisposition to Disease, education, education.field_of_study, epidemiology/genetics, business.industry, Multiple sclerosis, medicine.disease, Penetrance, Twin study, Confidence interval, Neurology, Italy, Regression Analysis, Settore MED/26 - Neurologia, Female, epidemiology, Neurology (clinical), Disease Susceptibility, business, Demography
Abstract: Knowledge about the balance between heritable and nonheritable risk in multiple sclerosis (MS) is based on twin studies in high-prevalence areas. In a study that avoided ascertainment limitations and directly compared continental Italy (medium-prevalence) and Sardinia (high-prevalence), we ascertained 216 pairs from 34,549 patients. This gives a twinning rate of 0.62% among MS patients, significantly less than that of the general population. In continental Italy, probandwise concordance was 14.5% (95% confidence interval, 5.1-23.8) for monozygotic and 4.0% (95% confidence interval, 0.8-7.1) for dizygotic twins. Results in Sardinia resemble those in northern populations but in limited numbers. Monozygotic concordance was 22.2% (95% confidence interval, 0-49.3) probandwise, but no concordant dizygotic pairs were identified. A questionnaire on 80 items possibly related to disease cause was administered to 70 twin pairs, 135 sporadic patients, and 135 healthy volunteers. Variables positively (7) or negatively (2) associated with predisposition and concordance in twins largely overlapped and were mainly linked to infection. If compared with previous studies, our data demonstrate that penetrance in twins appears to correlate with MS prevalence. They highlight the relevance of nonheritable variables in Mediterranean areas. The apparent underrepresentation of MS among Italian twins draws attention to protective factors, shared by twins, that may influence susceptibility.
Published: 2006

36. Consensus recommendations of the Italian Association for Neuroimmunology for immunochemical cerebrospinal fluid examination

Author: Franciotta, D., Avolio, C., Capello, E., Lolli, F., Aini Participating Members, M. Trojano, Leante, R., Falcone, M., Marrosu, M., Costa, G., MURRU, MR, Cocco, E., Gall, E., Chicchi, A., Maimone, D., Cuccia, S., Alessandra Lugaresi, Pantalone, A., Paolino, E., Castellazzi, M., Zaffaroni, M., Villa, C., Giunti, D., Panarese, C., Ribizzi, G., Vita, G., AGUENNOUZ, Ciranni, Am, Salmaggi, A., Bernardi, G., Ciusani, E., Passerini, G., Nobile-Orazio, E., Carpo, M., Allaria, S., Merelli, E., Bedin, R., Bertolotto, A., Sala, A., Gallo, P., Zardini, E., Andreoni, L., Siciliano, G., Bacci, A., Meucci, G., Simone, P., Desina, G., P DI VIESTI, Apollo, F., Sotgiu, S., Deiana, G., Annunziata, P., Morucci, A., Bonetti, B., Alberti, D., D FRANCIOTTA, C AVOLIO, E CAPELLO, F LOLLI, AINI PARTICIPATING MEMBERS M TROJANO, R LEANTE, M FALCONE, M MARROSU, G COSTA, MR MURRU, E COCCO, E GALL, A CHICCHI, D MAIMONE, S CUCCIA, A. LUGARESI, A PANTALONE, E PAOLINO, M CASTELLAZZI, M ZAFFARONI, C VILLA, D GIUNTI, C PANARESE, G RIBIZZI, G VITA, AGUENNOUZ, AM CIRANNI, A SALMAGGI, G BERNARDI, E CIUSANI, G PASSERINI, E NOBILE-ORAZIO, M CARPO, S ALLARIA, E MERELLI, R BEDIN, A BERTOLOTTO, A SALA, P GALLO, E ZARDINI, L ANDREONI, G SICILIANO, A BACCI, G MEUCCI, P SIMONE, G DESINA, P DI VIESTI, F APOLLO, S SOTGIU, G DEIANA, P ANNUNZIATA, A MORUCCI, B BONETTI, and D ALBERTI
Subjects: Oligoclonal bands, Standardization, MEDLINE, neuroimmunology, methods, standardization, consensus, Certification, Antibodies, NO, Multiple sclerosis, Resource (project management), Medicine, Animals, Humans, Antigens, Diagnostics, Cerebrospinal Fluid, Medical education, business.industry, Immunochemistry, Cerebrospinal fluid examination, Guideline, Joint research, Laboratory standardization, Neurology, Immunoglobulin G, Neurology (clinical), business, Neuroscience, Isoelectric focusing, Cerebrospinal fluid, Neurological diseases
Abstract: In 2002–2003, the Italian Association for Neuroimmunology (AINI) ran a program for procedure and method standardization in neuroimmunology. The main purposes of the program were: a) to improve the overall quality of analytical performance and, simultaneously, to reduce costs by resource optimization; b) to establish the bases for clinical guidelines in neurology; c) to promote the formation of laboratory networks and of joint research projects; d) to facilitate the procedures for certification required by governmental/non-governmental agencies. This report summarizes the consensus recommendations of a panel of AINI neuroimmunologists/biochemists involved in the field of cerebrospinal fluid examination. The collection process for said recommendations was guided by ‘‘impact-factored’’ literature and the knowledge of the experts involved. Communication was by email and face-to-face at two dedicated AINI workshops.
Published: 2005

37. Overexpression of autophagic proteins in the skeletal muscle of sporadic inclusion body myositis

Author: F, Girolamo, A, Lia, A, Amati, M, Strippoli, C, Coppola, D, Virgintino, L, Roncali, A, Toscano, L, Serlenga, and M, Trojano
Subjects: Adult, Male, Adolescent, Myositis, Biopsy, Molecular Sequence Data, Proteins, Middle Aged, ATG5, Autophagy, Beclin 1, Clathrin, Human myopathy, LC3, Rimmed vacuoles, SMI-31, Myositis, Inclusion Body, Young Adult, Humans, Female, Lysosomes, Muscle, Skeletal, Biomarkers, Aged
Abstract: Sporadic inclusion body myositis (s-IBM) is characterized by rimmed vacuole formation and misfolded protein accumulation. Intracellular protein aggregates are cleared by autophagy. When autophagy is blocked aggregates accumulate, resulting in abnormal rimmed vacuole formation. This study investigated the autophagy-lysosome pathway contribution to rimmed vacuole accumulation.Autophagy was studied in muscle biopsy specimens obtained from eleven s-IBM patients, one suspected hereditary IBM patient, nine patients with other inflammatory myopathies and nine non-myopathic patients as controls. The analysis employed morphometric methods applied to immunohistochemistry using the endosome marker Clathrin, essential proteins of the autophagic cascade such as AuTophaGy-related protein ATG5, splicing variants of microtubule-associated protein light chain 3a (LC3a) and LC3b, compared with Beclin 1, the major autophagy regulator of both the initiation phase and late endosome/lysosome fusion of the autophagy-lysosome pathway.In muscle biopsies of s-IBM patients, an increased expression of Clathrin, ATG5, LC3a, LC3b and Beclin 1 was shown. Moreover, the inflammatory components of the disease, essentially lymphocytes, were preferentially distributed around the Beclin 1(+) myofibres. These affected myofibres also showed a moderate sarcoplasmic accumulation of SMI-31(+) phospho-tau paired helical filaments.The overexpression of autophagy markers linked to the decreased clearance of misfolded proteins, including SMI-31, and rimmed vacuoles accumulation may exhaust cellular resources and lead to cell death.
Published: 2013

38. CSF MALDI-TOF mass spectrometry protein profiling in Clinically Isolated Syndrome

Author: Antonio Qualtieri, M. Liguori, C. Tortorella, V. Direnzo, A. Bagala', P. Spadafora, M. Mastrapasqua, and M. Trojano
Published: 2013

39. Fatigue and its relationships with cognitive functioning and depression in paediatric multiple sclerosis

Author: B, Goretti, E, Portaccio, A, Ghezzi, S, Lori, L, Moiola, M, Falautano, R, Viterbo, F, Patti, R, Vecchio, C, Pozzilli, V, Bianchi, S, Cappiello, G, Comi, M, Trojano, M P, Amato, M, Roscio, Goretti, B, Portaccio, E, Ghezzi, A, Lori, S, Moiola, L, Falautano, M, Viterbo, R, Patti, F, Vecchio, R, Pozzilli, C, Bianchi, V, Cappiello, S, Comi, Giancarlo, Trojano, M, and Amato, M.
Subjects: Male, medicine.medical_specialty, Multiple Sclerosis, Adolescent, Neuropsychological Tests, children and adolescents, cognitive impairment, multiple sclerosis, fatigue, Cohort Studies, Young Adult, Multiple Sclerosis, Relapsing-Remitting, Quality of life, medicine, Humans, Cognitive skill, Child, Depression (differential diagnoses), Fatigue, Depressive Disorder, Depression, Cognition, Neurology, Cohort, Physical therapy, Female, Neurology (clinical), Psychiatric interview, Psychology, Cognition Disorders, Psychosocial, Clinical psychology, Cohort study
Abstract: Background: There is limited information on fatigue and its clinical and psychosocial correlates in children and adolescents with multiple sclerosis (MS). Objective: To assess the relationships between fatigue, cognitive functioning and depression in paediatric MS. Methods: The study cohort consisted of patients with MS recruited for an Italian collaborative study on cognitive and psychosocial functioning in paediatric MS. The present assessment included evaluation of fatigue on the Pediatric Quality of Life Inventory-Multidimensional Fatigue Scale, cognitive functioning on an extensive neuropsychological battery and depression on the Children’s Depression Inventory (CDI). A psychiatric interview through the Kiddie-SADS-Present and Lifetime Version was also administered. Results: In total, 57 patients with relapsing–remitting MS were compared with 70 healthy controls. Percentages of fatigued patients ranged from 9% to 14% according to self-reports, and from 23% to 39% according to parent reports. Fatigue was significantly related with higher scores on the CDI ( p < 0.03). Higher levels of self-reported cognitive fatigue were associated with impaired performance on a problem-solving test, whereas higher levels of parent-reported cognitive fatigue were associated with impairment on tests of verbal learning, processing speed, complex attention and verbal comprehension. Conclusions: Our data show that fatigue can affect a sizeable proportion of paediatric MS patients, and confirm the association between fatigue and depressive symptoms in MS. They also highlight the difficulties of fatigue assessment in the paediatric population and provide a few clues to further research in the field.
Published: 2011

40. Ile587Val polymorphism of the eIF2B5 gene as susceptibility factor for multiple sclerosis

Author: C Ungaro, FL Conforti, M Trojano, F Condino, I Manna, V Andreoli, A Patitucci, AL Gabriele, A Magariello, L Citrigno, W Sproviero, M Muglia, A Gambardella, and R Mazzei
Published: 2010

41. observational studies: propensity score analysis of non-randomized data

Author: M, Trojano, F, Pellegrini, D, Paolicelli, A, Fuiani, and V, Di Renzo
Subjects: Disability Evaluation, Multiple Sclerosis, Relapsing-Remitting, Treatment Outcome, Adjuvants, Immunologic, Bias, Antirheumatic Agents, Antibodies, Monoclonal, Humans, Observation, Multiple Sclerosis, Chronic Progressive, Propensity Score, Randomized Controlled Trials as Topic
Abstract: The randomized controlled trial (RCT) is considered to be the "gold standard" for providing evidence on drug efficacy. However, particularly for answering long-term questions in chronic diseases such as multiple sclerosis (MS), RCTs are often not feasible because of their size, duration, ethical constraints and costs. Data derived from observational studies complement information provided by RCTs. A major issue is that observational studies are more exposed and prone to biases, which can partly be addressed through rigorous study design or statistical analysis. Propensity score (PS) techniques are the most frequently used. PS is the probability that an individual would receive a certain treatment based on his/her pretreatment characteristics. This score is being widely used in many therapeutic areas and also in MS to adjust for the uncontrolled assignment of treatment in observational studies. However, since PS cannot adjust for unmeasured or unknown confounders, the conclusions from an observational study may not be considered as strong as those from RCTs.
Published: 2009

42. Multiple sclerosis: polymorphism ILE587VAL in the eIF2B5 gene as susceptibility factor

Author: C Ungaro, FL Conforti, M Muglia, A Patitucci, AL Gabriele, A Magariello, L Citrigno, W Sproviero, M Liguori, M Trojano, A Gambardella, and R Mazzei
Published: 2009

43. Is it time to use observational data to estimate treatment effectiveness in multiple sclerosis?

Author: D. E. Wilkins and M. Trojano
Subjects: Multiple Sclerosis, Bias, Research Design, Humans, Neurology (clinical), Randomized Controlled Trials as Topic
Published: 2008

44. Italian studies on early onset multiple sclerosis: the present and the future

Author: Ghezzi A, Ruggieri M, Trojano M, Filippi M and ITEMS Study Group
Subjects: treatment, therapies, multiple sclerosis, childhood
Published: 2004

45. Association study between synapsin III gene and Multiple Sclerosis (MS)

Author: M.Liguori, I. Manna, P. Valentino, A. Clodomiro, M. Trojano, A La Russa, R. Cittadella, P Serra, D. Messina, F.Rustica, P.Livrea, and A. Quattrone.
Published: 2003

46. Serum soluble intercellular adhesion molecule-I in MS: relation to clinical and Gd-MRI activity and to rIFN beta-Ib treatment

Author: M, Trojano, C, Avolio, M, Ruggieri, G, Defazio, F, Giuliani, D, Paolicelli, and P, Livrea
Subjects: Adult, Gadolinium DTPA, Male, Multiple Sclerosis, Contrast Media, Interferon-beta, Image Enhancement, Intercellular Adhesion Molecule-1, Magnetic Resonance Imaging, Recombinant Proteins, Adjuvants, Immunologic, Solubility, Humans, Female, Interferon beta-1a, Interferon beta-1b
Abstract: The validity of serum sICAM-I levels to assess Multiple Sclerosis (MS) activity was evaluated in 49 untreated definite relapsing-remitting (RR) patients. sICAM-I levels were significantly (P = 0.0009) higher in the 'clinically active' group (No 22) than in the 'clinically inactive' (No 27), whereas no different values were found between patients with Gd-enhancing lesions at MRI (Gd-positive) (No 32) and patients without such lesions (Gd-negative) (No 17) independently of their clinical activity. Among the 'clinically active' MS, the Gd-positive (No 16) subgroup showed significant (P0.05) lower sICAM-I levels when compared to the Gd-negative (No 6) subgroup, but higher (P = 0.009) than those of the 'clinically inactive Gd-positive' (No 16) patients. The sICAM-I levels did not differ between the two 'clinically inactive' subgroups Gd-positive (No 16) and Gd-negative (No 11). Finally the clinically active Gd-negative (No 6) showed sICAM-I levels higher (P = 0.002) than the clinically inactive Gd-negative (No 11). The specificity of high serum sICAM-I levels (above M +/- 2 s.d. of control values) to assess the disease activity in MS resulted higher (100%) using clinical than Gd-MRI activity (76%) as gold standard. The changes induced by 1 year recombinant Interferon-beta-Ib (rIFN beta-Ib) treatment on sICAM-I serum levels were also longitudinally investigated in 36 of the 49 RR MS. sICAM-I levels at baseline significantly increased in the first 2 months (baseline vs 1st month P0.0001 and 1st vs 2nd month P = 0.02), persisted at high levels without any significant change after 3 months, showed a temporary decrease at 6 months, then significantly increased again at 9 and 12 months. Fourteen patients experienced relapses, with a total of 20 relapses, during the whole treatment duration. The mean relapse/rate and the frequency of patients with Gd-positive MRI scans resulted significantly higher in the first semester compared to the second semester of treatment. This study adds further insights into the validity of serum sICAM-I to assess disease activity in MS and on the immunomodulatory properties of rIFN beta-Ib.
Published: 1998

47. Soluble intercellular adhesion molecule-I (sICAM-I) in serum and cerebrospinal fluid of demyelinating diseases of the central and peripheral nervous system

Author: M, Trojano, C, Avolio, M, Ruggieri, F, De Robertis, F, Giuliani, D, Paolicelli, and P, Livrea
Subjects: Adult, Central Nervous System, Male, Multiple Sclerosis, Polyradiculoneuropathy, Interferon-beta, Middle Aged, Recombinant Proteins, Solubility, Adrenal Cortex Hormones, Blood-Brain Barrier, Peripheral Nervous System, Humans, Female, Cell Adhesion Molecules, Aged
Abstract: Serum and cerebrospinal fluid (CSF) soluble intercellular adhesion molecule-I (ICAM-I) levels were evaluated (ELISA) in 22 untreated and 13 corticosteroid-treated active relapsing remitting (RR) Multiple Sclerosis (MS), in 10 untreated and 10 corticosteroid-treated Guillain-Barré syndrome (GBS) and in 17 non-inflammatory neurological diseases (NIND). Twenty-eight clinically inactive RR MS were assayed for serum sICAM-I before and after 3 months treatment of 8 MIU rIFN beta-Ib taken s.c. every other day. High sICAM-I serum levels above the NIND values were found in untreated clinically active MS and in untreated GBS (P0.05) but not in the untreated clinically inactive MS group. The active MS group showed significantly (P = 0.0001) higher sICAM-I serum levels if compared to the inactive group. Corticosteroid-treated active MS and GBS patients showed lower (P0.05) serum sICAM-I levels than the corresponding untreated groups. Serum sICAM-I levels after 3 months of rIFN beta-Ib treatment (P0.0001, paired t-test) resulted increased compared to pretreatment values in MS. The mean values of CSF/serum sICAM-I:CSF/serum Albumin ratios (sICAM-I Index) in active untreated MS patients were higher compared to NIND (P0.005) and to corticosteroid-treated MS group (P = 0.01). sICAM Index values in GBS did not differ from those in NIND. The results seem to suggest potential roles for serum sICAM-I in downregulating the ongoing inflammatory response at the blood-brain barrier level and for CSF sICAM-I in the maintenance of a central nervous system local immune response.
Published: 1998

48. Cerebrospinal Fluid Analysis in Multiple Sclerosis

Author: E. J. Thompson, M. Trojano, and P. Livrea
Published: 1996

49. PREDICTORS OF POSTPARTUM RELAPSES IN WOMEN WITH MULTIPLE SCLEROSIS: RESULTS FROM THE MSBASE REGISTRY

Author: SA Hawkins, C Boz, Orla Gray, F Kee, GV McDonnell, Stella Hughes, M Trojano, Helmut Butzkueven, and T Spelman
Subjects: Pregnancy, medicine.medical_specialty, Expanded Disability Status Scale, business.industry, Obstetrics, Multiple sclerosis, Relapse rate, medicine.disease, Logistic regression, Third trimester, Surgery, Psychiatry and Mental health, medicine, Observational study, Neurology (clinical), business, Early postpartum
Abstract: Background Several studies have shown that pregnancy reduces relapse rate in Multiple Sclerosis (MS), followed by an increased relapse rate in the early postpartum period. We re-examined the effect of pregnancy on MS using the international MSBase Registry, examining predictors of early post-partum relapse. Methods We performed a prospective observational multi-centre case-control study, with self-control. Annualised relapse rate (ARR) and median Expanded Disability Status Scale (EDSS) scores were compared for the 24 months pre-conception, pregnancy and 24 months postpartum periods. Clustered logistic regression was used to investigate predictors of early postpartum relapses. Results We included 893 pregnancies in 674 females with MS. Mean ARR (SD) for 24 months pre-pregnancy was 0.32 (0.45), decreasing to 0.13 (0.77) by 3rd trimester of pregnancy. ARR rose to 0.61 (1.61) in the 1st 3 months postpartum, and returned to baseline by 24 months. Median EDSS remained stable. Higher pre-conception ARR predicted early postpartum relapse and an independent protective effect was observed with disease-modifying treatment (DMT) use in the 2 years pre-conception. Conclusion We confirm a favourable effect of pregnancy on relapse rate in MS, strongest in the third trimester, and a peak in relapses in the early postpartum period. In the pre-conception period, DMT exposure and low ARR conferred independent protective effects for postpartum relapse. This novel finding could provide clinicians with a strategy to minimise risk of postpartum relapse in women with MS planning pregnancy.
Published: 2012

50. [Sporadic distal myopathy with early onset. Description of a case]

Author: G, Pozio, M, Trizio, M, Trojano, L, Lochi, and L, Serlenga
Subjects: Adult, Muscular Diseases, Humans, Female
Published: 1986

Catalog

Books, media, physical & digital resources

See catalog results

Searchworks

Select search scope, currently: Articles Catalog books, media & more in Jio Institute collections Articles journal articles & other e-resources

Search

Search Constraints

Refine your results

Search Limiters

Topic

Publication Year Range

Language

Publication Type

Journal

Region

Database

Publisher

488 results on '"M Trojano"'

Search Results

Catalog

Select search scope, currently: Articles

Catalog

books, media & more in Jio Institute collections

Articles

journal articles & other e-resources